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ABSTRACT 
Toll-like receptor 9 (TLR9) activates the innate immune system in response to 
microbial DNA or mimicking oligodeoxynucleotides.  While the discrimination of host 
and microbial DNA is presumed to reflect TLR9-mediated recognition of CpG motifs, 
little information is available to verify this hypothesis.  Cell stimulation experiments 
demonstrate preferential activation of TLR9 by CpG-containing nucleic acids, however 
direct binding investigations have reached contradictory conclusions with respect to the 
ability of TLR9 to bind nucleic acids in a sequence-specific fashion.  Here we report 
expression of the soluble, ectodomain of human TLR9 with characterization of its 
ligand-binding properties.  TLR9 has a high degree of ligand specificity in being able to 
discriminate not only CpG dinucleotides, but also higher order six nucleotide motifs that 
mediate species-specific activation.  However, TLR9 ligand binding is also functionally 
influenced by nucleic acids in a sequence-independent manner both in vitro and in cell 
proliferation experiments.  A model is proposed in which TLR9 activation is mediated 
specifically by CpG-containing ligands while sensitivity is mediated specifically by the 
absolute concentration of nucleic acids in a sequence-independent manner. 
The bovine hsp70A promoter was used to direct the heat-regulated synthesis of 
the ectodomain of human TLR9 in transfected cultured bovine cells.  The protein was 
efficiently secreted from transfected cells in a temperature-dependent manner and the 
recombinant receptor produced was found to be relatively pure.  A stably transfected 
cell line with regulated expression of the protein was obtained and repeated thermal 
cycling of the cultures enabled high-yield production of the receptor in an active ligand-
binding form.  Using this recombinant receptor to study the ligand binding properties of 
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TLR9, a model of positive cooperativity is proposed in which the sensitivity of TLR9 
ligand binding is modulated by the absolute concentration of nucleic acids in a 
sequence-independent fashion, while activation of TLR9 is highly dependent on DNA 
sequence.  That is to say that TLR9 is ‘primed’ for activation by interaction with non-
activating sequences but activation itself occurs in a sequence-specific fashion. 
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1.0 LITERATURE REVIEW 
 
1.1 Mammalian Immunity 
The mammalian immune system protects the host from infection through the 
identification and neutralization of pathogens.  The difficulty inherent in this task is that 
pathogens present themselves in a variety of forms, ranging from parasites to bacteria, 
and these threats must be detected with specificity amongst normal tissues and cells.  In 
addition, the immune system has also served as an evolutionary pressure to drive 
pathogens to evolve active strategies to avoid detection by the immune system (Basset, 
Holton et al. 2003; Ulevitch 2004).  To meet these challenges, the mammalian immune 
system has evolved multiple mechanisms and overlapping systems to ensure efficient 
recognition of a diverse spectrum of potential microbial invaders.  These immune 
systems consist of two distinct, but interconnected and complimentary branches – 
adaptive and innate immunity.   
The innate and adaptive immune systems protect the host from the threat of 
infection with layered defenses of increasing specificity.  If a pathogen breaches the 
body’s physical barriers, the innate immune system provides an immediate, non-specific 
response.  Innate immunity therefore refers to non-specific defense mechanisms that are 
activated immediately upon recognition of biomolecules associated with microbes 
(Hoffmann, Kafatos et al. 1999).  If a pathogen escapes the defenses of the innate 
immune system, the adaptive immune system is then activated to initiate 
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responses which are specific to that pathogen.  This system adapts, or changes, over 
time in order to recognize particular pathogens more effectively.  Adaptive immunity 
creates immunological memory, which allows more effective and efficient protection 
against pathogens previously encountered by the host (Hoebe, Janssen et al. 2004; Tosi 
2005).  Adaptive immunity is defined by antigen-specific immune responses, 
specifically those generating immunological memory for rapid clearance of pathogens 
already encountered by the system.  These two systems do not function as distinct 
entities, as the adaptive immune system is activated by the innate immune system 
(Medzhitov and Janeway Jr. 1997).   
 
1.1.1 Innate and Adaptive Immunity 
Innate immunity is the first line of host defense response which acts immediately 
following infection to prevent further invasion by the pathogen (Hoffmann, Kafatos et 
al. 1999).  Recognition of foreign molecules/antigen by the innate immune system, and 
distinguishing self molecules from non-self, relies on pattern recognition receptors 
(PRRs).  These receptors recognize conserved microbial molecular patterns which are 
highly conserved across a wide range of bacterial and viral species and are largely 
absent from the host anthology of biomolecules (Medzhitov and Janeway Jr. 1997).  The 
innate immune system is made up of cells and signaling pathways which defend the host 
from infection by foreign organisms.  The cells, and associated response mechanisms, 
recognize and respond to pathogens non-specifically and do not confer long-term 
protective immunity to the host.  The innate immune system responses involve various 
effector mechanisms including, but not limited to, phagocytosis by macrophages, the 
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production of antimicrobial compounds and the production of cytokines and chemokines 
which mediate the recruitment of inflammatory cells (Hoffmann, Kafatos et al. 1999; 
Janeway Jr. and Medzhitov 2002).   
The innate immune system is an evolutionarily older defense mechanism than the 
adaptive immune system, and it is present in insects, plants, fungi, and other primitive 
organisms (Medzhitov and Janeway Jr. 2000).  Whereas vertebrates also rely on the 
adaptive immune responses, invertebrates rely solely on the mechanisms of the innate 
immune system to combat infection – a testament to the strength of the innate immune 
system.  The major functions of the vertebrate innate immune system include (Murray, 
Rosenthal et al. 2002): 
• activation of mechanisms, such as the complement cascade, to identify bacteria 
and to activate cells which promote clearance of dead cells or antibody 
complexes 
• recruitment of immune cells to the site(s) of infection  
• inflammation via production of cytokines and chemokines 
• identification and removal of foreign substances by specialized white blood 
cells (lymphocytes), and 
• activation of the adaptive immune system through antigen presentation. 
 
In contrast, adaptive immunity is activated in vertebrates when a pathogen 
successfully evades the innate immune system.  While the details of activation of 
adaptive immunity are outside the scope of this thesis, the major functions of the 
adaptive immune system include (Janeway 2001): 
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• discrimination of self antigens from non-self during antigen presentation by the 
innate immune system 
• generation of specific responses to eliminate specific pathogens or pathogen-
infected cells, and 
• development of immunological memory, whereby each pathogen is recognized 
by, or associated with, a signature antigen; memory cells can be called upon to 
readily eliminate a pathogen should subsequent infection occur. 
 
1.1.2 How Adaptive Immunity Recognizes Non-Self 
As the focus of this thesis is on how a specific component of the innate immune 
system, Toll-like Receptor 9 (TLR9), recognizes pathogens, only a brief description of 
the recognition mechanisms employed by the adaptive immune system will be presented 
as a point of comparison. 
The adaptive immune system is composed of highly specialized cells and 
processes that eliminate pathogenic challenges (Chaplin 2003).  The adaptive immune 
response provides the immune system with the ability to recognize and remember 
specific pathogens, to generate immunity, and to mount stronger attacks each time the 
pathogen is encountered (Hoebe, Janssen et al. 2004).  This serves to prepare the body 
for future challenges.  This ability relies on the diversity of antigen receptors, designed 
to specifically recognize a virtually unlimited panel of antigens.  This is achieved by 
localized somatic mutations and recombination/rearrangement of gene segments within 
the B cell antigen receptors (Diaz and Flcjnik 1998).  These gene rearrangements lead to 
irreversible changes in the DNA of each cell and, as such, all progeny of the original cell 
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will inherit genes encoding the same receptor specificity, including B and T memory 
cells, which are the key to long-lasting specific immunity (Janeway 2001; Janeway Jr. 
and Medzhitov 2002).  This diversity allows a small number of genes to generate a large 
number of different antigen receptors that can be expressed uniquely on individual cells. 
Adaptive immunity also relies on the capacity of immune cells to distinguish 
between the body’s own cells and invading cells, as host cells express self antigens 
which are different from the non-self antigens found on the surface of bacterial cells or 
on virally-infected host cells (Medzhitov and Janeway Jr. 2000).  The adaptive response 
is triggered by the recognition of these non-self antigens.  The adaptive immune system 
of lymphocytes, which express a single receptor on each cell, is selected positively by 
self-antigens, and negatively by self-antigens which could potentially cause autoimmune 
disease (Medzhitov and Janeway Jr. 2000; Monroe, Bannish et al. 2003). 
All nucleated cells expressing major histocompatibility (MHC) class I or II 
molecules have the capacity to activate the adaptive immune response through 
presentation of antigen (Janeway 2001).  Different cell subsets, including dendritic cells 
(DCs), B cells and macrophages, express immunostimulatory receptors which allow 
enhanced activation of T cells.  These are termed professional antigen presenting cells 
(APCs).  Several subgroups of  T cells can be activated by professional APCs, and each 
type of T cell is equipped to deal specifically with unique pathogens (Taams, van Eden 
et al. 1999).  The type of response generated depends on the type of T cell activated, and 
this depends largely on the context in which the APC encounters the antigen.   
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1.1.3 How Innate Immunity Recognizes Non-Self 
1.1.3.1 Pattern Recognition Receptors 
In contrast to adaptive immunity, which has the potential to generate a virtually 
limitless number of protein recognition molecules specific to particular antigens, the 
innate immune system utilizes only a limited number of receptors for recognition of an 
equally limited number of targets.  These receptors recognize the core building blocks 
from which their targets are constructed; nucleic acids (DNA and RNA) and protein 
components such as lipopolysaccharides, etc. 
Recognition of non-self antigens by the innate immune system relies on 
germline-encoded pathogen recognition receptors, PRRs, which recognize conserved 
microbial molecular patterns (pathogen-associated molecular patterns, PAMPs) (Gordon 
2002).  PRRs are proteins expressed by cells of the immune system to identify 
molecules associated with microbial pathogens – PAMPs.  These receptors are 
categorized according to their ligand specificities, function and location within the cell.   
 Two of the primary classes of PRRs can be described by their cellular location; 
the TLR family, which are membrane-associated, and the nucleotide-oligomerization 
domain (NOD)-like receptors (NLRs) which occupy cytoplasmic locations. 
 
1.1.3.2 Nucleotide-oligomerization domain-containing receptors and NACHT-
LRR-PYD containing proteins 
The NLRs are cytoplasmic proteins that appear to function in the regulation of 
inflammatory responses and apoptotic pathways (Inohara, Chamaillard et al. 2005; 
Strober, Murray et al. 2006).  The NOD-like nomenclature arises because all of the 
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members of this family contain nucleotide-oligomerization domains (NODs).  
Approximately twenty of these proteins have been identified in the mammalian 
proteome and include two major subfamilies called NODs and NALPs [neuronal 
apoptosis inhibitory protein, MHC class II transcription activator, incompatibility locus 
protein from Podospora anserina, and telomerase-associated protein (NACHT)- 
leucine-rich repeat (LRR)- pyrin domain (PYD)-containing proteins].  Current 
knowledge suggests that these families of proteins recognize microbial molecules or 
stress responses and form receptor oligomers to activate inflammatory responses.  These 
responses include activation of inflammatory cytokines and/or activation of the NF-κB 
signaling pathway to induce production of other varieties of inflammatory molecules to 
initiate the inflammatory response (Chamaillard, Girardin et al. 2003; Fritz, Ferrero et 
al. 2006).  These families of proteins have conserved structural and functional elements.   
As shown in Figure 1.1, the NOD receptors are characterized by a C-terminal 
LRR domain, a central NACHT domain, followed by a NACHT-associated domain 
(NAD) and an N-terminal protein-protein interaction domain which is either a caspase 
activating and recruitment domain (CARD) or pyrin domain (PYD) (Inohara, 
Chamaillard et al. 2005; Fritz, Ferrero et al. 2006; Strober, Murray et al. 2006).  Within 
the NLRs, the LRR represents the ligand-binding domain; similarly TLRs also use LRR 
domains to mediate ligand binding.  The protein-protein interaction domains, either 
CARD or PYD, serve to mediate interactions with CARD- or PYD-containing 
intracellular adapter molecules, respectively, that initiate signal transduction events.  
Within the TLRs a similar requirement is fulfilled with the TIR domains.   
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CARD NACHT LRR NAD
 
 
Figure 1.1.  Domain comparison of pattern recognition receptors.  NLRs (NOD, 
NALP) contain a protein-protein interaction domain, CARD or PYD, homologous to the 
TIR domain of TLRs.  All PRRs contain LRR motifs required for ligand binding.  
CARD: caspase activating and recruitment domain, NACHT: neuronal apoptosis 
inhibitory protein, MHC class II transcription activator, incompatibility locus protein 
from Podospora anserina, and telomerase-associated protein, NAD: NACHT-associated 
domain, LRR: leucine-rich repeat, PYD: pyrin domain, TIR: Toll/interleukin-1 receptor, 
TM: transmembrane domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOD1 
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NOD1 contains CARD, LRR and NACHT domains.  The adaptor protein Rip2, 
which is homologous to the TLR adaptor protein IRAK, also contains a CARD domain 
and leads to activation of NF-κB via the IKK signalsome (Chamaillard, Girardin et al. 
2003).  NOD2 is structurally very similar to NOD1, but contains two CARD domains, 
rather than one.   
Currently, there are many NODs for which ligands have yet to be identified.  
There are few NODs to which the ligands have been assigned; NOD1 receptors 
recognize a molecule called meso-diaminopimelate (meso-DAP), a unique muropeptide 
peptidoglycan component found only in Gram negative bacteria.  NOD2 receptors 
recognize intracellular muramyl dipeptide (MDP), which is the minimal bioactive 
peptidoglycan motif common to all bacteria (Franchi, McDonald et al. 2006).     
Like NODs, NALPs contain C-terminal LRRs, which appear to act as regulatory 
domains involved in the recognition of invading pathogens.  Also like NODs, these 
proteins contain a nucleotide binding site (the NACHT domain).  Interaction with other 
proteins is mediated via N-terminal pyrin domain (PYD), rather than CARD.  There are 
currently fourteen known members of the NALP subfamily.  Activating ligands for 
NALPs include muramyl didpeptide, ATP, double-stranded RNA, and bacterial DNA 
(Strober, Murray et al. 2006) (Table 1.1).   
 In contrast to the recognition of cytosolic PAMPs by the NODs and NALPs, 
recognition of extracellular or endosomal PAMPs is mediated by the TLR family of 
receptors (Beutler, Jiang et al. 2006).  These receptors are known to initiate a series of 
signaling pathways that culminate in the synthesis and secretion of cytokines and 
activation of other host defense programs central to the development of an immune  
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Table 1.1.  Known ligands for known pattern recognition receptors.  Ligands are 
known for the majority of the TLRs, while the ligands for most of the NLRs remain 
unknown.  NOD1/2 and NALP1/3 are representative of this family of receptors. 
 
Receptor Known ligand(s) Cellular Location 
NOD1 Meso-diaminopimelate Cytosol 
NOD2 Intracellular muramyl dipeptide Cytosol 
NALP1 Muramyl dipeptide Cytosol 
NALP3 Muramyl dipeptide Cytosol 
TLR1 Triacyl lipoproteins Plasma membrane 
TLR2 
Lipoproteins, Gram-positive 
peptidoglycan, lipoteichoic 
acids 
Plasma membrane 
TLR3 
Double-stranded RNA, poly 
I:C 
Endosome 
TLR4 Lipopolysaccharide Plasma membrane 
TLR5 Bacterial flagellin Plasma membrane 
TLR6 Diacyl lipoproteins Plasma membrane 
TLR7 
Single-stranded RNA, small 
synthetic compounds 
Endosome 
TLR8 
Single-stranded RNA, small 
synthetic compounds 
Endosome 
TLR9 Unmethylated CpG DNA Endosome 
TLR11 Profilin ? 
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response (Doyle and O'Neill 2006).  The TLRs, specifically TLR9, will be the focus of 
this thesis and will be discussed in greater detail. 
 
1.2 Toll-like Receptors 
TLRs are a family of type I transmembrane PRRs involved in recognition of a 
wide range of PAMPs, from bacterial DNA and cell wall components to viral RNA 
(Krutzik, Sieling et al. 2001; Janeway Jr. and Medzhitov 2002; Kaisho and Akira 2002; 
Underhill and Ozinsky 2002).  The TLR family is highly conserved in vertebrates, with 
the identification of thirteen members in mammals and ten human homologues as of 
2004 (Medzhitov, Preston-Hurlburt et al. 1997; Chaudhary, Ferguson et al. 1998; Rock, 
Hardiman et al. 1998; Takeuchi, Kawai et al. 1999; Chuang and Ulevitch 2000; Du, 
Poltorack et al. 2000; Chuang and Ulevitch 2001; Dunne and O'Neill 2003; Zhang, 
Zhang et al. 2004) (Table 1.2, Table 1.3).  These receptors are composed of an 
extracellular domain, or ectodomain, which is characterized by repeating units of a 
leucine-rich motif, and an intracellular signaling domain that shares homology with the 
mammalian IL-1 receptor (IL-1R), known as the Toll/IL-1R (TIR) domain (Figure 1.2).  
Overall evidence would suggest that PAMPs trigger signaling responses through 
interaction with the ectodomain of these receptors leading to activation of NF-κB 
through conserved TLR signaling pathways.  However, the mechanisms by which these 
ligands are recognized and how this recognition ultimately leads to TLR signaling are 
currently not well-understood. 
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Table 1.2.  Number of amino acids, leucine-rich repeats and molecular weights of 
human Toll-like receptors 1-10.  GenBank ascension numbers of the receptors are also 
included.  
 
 
TLR Amino acids LRRs MW (kDa) Ascension # 
1 786 18 84 U88540 
2 784 19 84 U88878 
3 904 24 97 U88879 
4 839 22 90 H48602 
5 858 23 91 U88881 
6 796 20 91 AB020807 
7 1049 27 121 AF240467, AF245702 
8 1041 26 120 AF245703, AF246971 
9 
1032 
27 116 
AF245704, 
AF259262, AF259263 
10 811 ? 95 AF296673 
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Table 1.3.  Sequence comparison of human Toll-like receptors 1-10.  Values result 
from comparison of the entire sequences of all 10 TLRs and values are percent amino 
acid sequence identity.  GenBank ascension numbers are as follows:  TLR1 [U88540], 
TLR2 [U88878], TLR3 [U88879], TLR4 [H48602], TLR5 [U88881], TLR6 
[AB020807], TLR7 [AF240467], TLR8 [AF245703], TLR9 [AF245704], TLR10 
[AF296673]. 
 
 
TLR 1 2 3 4 5 6 7 8 9 10 
1 100 29 23 25 22 68 21 23 22 48 
2  100 22 26 23 31 24 24 25 29 
3   100 24 26 23 26 26 24 24 
4    100 24 25 23 24 24 23 
5     100 23 24 25 24 22 
6      100 22 22 22 46 
7       100 43 36 22 
8        100 35 21 
9         100 21 
10          100 
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mammalsDrosophila  
 
Figure 1.2.  Drosophila Toll and homologous mammalian receptors;  interleukin-1 
receptor (IL-1R) and Toll-like receptor (TLR).  The extracellular regions of Toll and 
TLR4 contain multiple leucine-rich repeats (LRRs, each      representing one such 
repeat) for ligand binding, while that of IL-1R contains three immunoglobulin (Ig) 
domains (  ).  The cytoplasmic domains of all three receptors contain the 
Toll/interleukin-1 receptor (TIR,  ) domain for interaction with TIR domain-containing 
adaptor molecules which activate downstream signaling cascades.  The hydrophobic 
core of the LRR is often capped with cysteine-rich sequences (      ). 
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1.2.1 Drosophila Toll 
The discovery of the TLRs was initiated by investigations of Toll.  The first 
member of the Toll family of receptors was identified in Drosophila melanogaster, 
where it was shown to be one of twelve maternal genes involved in embryonic 
dorsoventral patterning (Hashimoto, Hudson et al. 1988; Belvin and Anderson 1996).   
Further investigations indicated that Toll was also important in the control of 
infections by Gram-positive bacteria and fungi (Imler and Hoffmann 2001).  The 
involvement of this receptor in mediating innate immune responses led to the discovery 
of sequence homology between the cytoplasmic domains of Drosophila Toll and human 
interleukin-1 receptor and eventually to the discovery of the TLRs in vertebrates (Gay, 
Packman et al. 1991; Rock, Hardiman et al. 1998).  In addition to serving as the stimulus 
for the discovery of the TLRs, Toll has also been proven to be a valuable model for 
understanding specific mechanisms of TLR function and as such will be discussed in 
some detail. 
 
1.2.1.1 Toll Function 
The first member of the Toll family of receptors, Toll, was not based on its 
function as a PRR in innate immune activation.  Initially Toll was found to control 
dorsoventral axis formation in the Drosophila embryo.  The two primary axes of the 
Drosophila embryo, anterior-posterior and dorsal-ventral, are established by the action 
of two sets of maternal effect genes (Nusslein-Volhard 1979).  Maternal effect genes are 
maternally-produced and affect the early developmental processes of the embryo.  One 
of the maternal effect dorsal-group genes is Toll.  Females carrying mutations in the Toll  
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gene produce embryos that have a variety of alterations in their dorsal-ventral pattern 
(Anderson, Jurgens et al. 1985).  Loss-of-function alleles produce dorsalized embryos as 
a recessive maternal effect, while dominant gain of function alleles result in ventralized 
embryos.  Other recessive alleles cause partial dorsalization or lateralization of the 
embryonic pattern.  Double mutant phenotypes suggest that the products of other dorsal-
group genes regulate the activity of Toll.  
Further investigation of genes in the dorsalization/ventralization pathway 
indicated that the Toll ligand Spätzle, adapter protein Tube, protein kinase Pelle, 
transcription factor Dorsal and a Dorsal inhibitor, Cactus, were also involved in the Toll 
system.  Later, the role of Toll in innate immunity was proposed because of noted 
homology between Toll and the human IL-1 receptor.  The intracellular domains of the 
two receptors are homologous, suggesting conserved function (Janeway Jr. and 
Medzhitov 2002).  It was found that activation of either receptor results in NF-κB 
activation.  Individual receptors within the Toll family, including 18-wheeler and Imd, 
interact with different combinations of adaptor proteins and activate various 
transcription factors, including NF-κB, activating protein-1 (AP-1) and interferon 
regulatory factors (IRFs), driving innate immune responses (Kawai and Akira 2006). 
With loss-of-function mutations to spätzle, tube or pelle, fruitflies become highly 
susceptible to fungal infections (Lemaître, Nicolas et al. 1996), indicating that the Toll 
pathway controls not only dorsoventral patterning in embryos, but also the antifungal 
immune response in the adult fly.      
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1.2.1.2 Toll Structure 
Toll is a 135 kDa transmembrane protein with a large extracellular domain and a 
cytoplasmic domain of 269 amino acids (Winans and Hashimoto 1995) (Figure 1.3).   
The ligand-binding region of Toll contains twenty-two LRRs and carboxy-terminal 
cysteine-rich domains.  The ectodomains of these receptors contain blocks of repeats of 
a twenty-four amino acid motif, the leucine-rich repeat, usually with a cysteine-rich 
capping structure at the amino- and carboxy-termini of each block.  Toll receptors have 
two discrete blocks of LRRs and associated capping structures (Chang, Pili-Floury et al. 
2004).  The LRR units fold into a curved, solenoidal structure, and the sequence 
conservation reflects the requirements for this structural scaffold, with the conserved 
residues forming the hydrophobic core of each LRR (Bell, Mullen et al. 2003).  The C-
terminal capping structure of Toll is connected to a single transmembrane α-helix and 
the cytoplasmic domain, known as the TIR domain or TIR identity region, which 
couples downstream signal transduction to receptor engagement.  Members of the Toll 
and TLR families share a conserved molecular structure (Rock, Hardiman et al. 1998). 
The basic mechanism of signaling by Toll, and by TLRs, seems to involve 
ligand-induced dimerization or oligomerization.  The evidence for this comes from 
experiments that examined the interaction of Spätzle with Toll.  These studies showed 
that the binding of Spätzle crosslinks two Toll ectodomains in a symmetrical complex.  
This crosslinking is necessary and sufficient for signal transduction by Toll (Weber, 
Tauszig-Delamasure et al. 2003).  Recent evidence also indicates that a similar 
mechanism likely applies to vertebrate TLRs.                  
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LRR 
N-terminal Cys-rich 
C-terminal Cys-rich 
Transmembrane domain 
TIR domain 
C 
Figure 1.3.  Drosophila Toll.  The receptor is characterized by a large region of leucine-
rich repeats (LRRs,       ) in the ectodomain, N- and C-terminal cysteine-rich domains     
(     ), a transmembrane domain (    ) and a cytoplasmic Toll/interleukin-1 receptor   
(TIR,  ) domain.  The ectodomain is the ligand binding region of the receptor and the 
cytoplasmic TIR domain, the intracellular signalling domain which interacts with TIR-
containing adapter molecules. 
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Chimeric TLR4 molecules in which the TLR4 ectodomain is replaced with that 
of Toll are activated by Spätzle with very similar biochemical characteristics to those 
shown by intact Toll (Weber, Tauszig-Delamasure et al. 2003).  This finding indicates 
that the TIR domains of two chimeric TLR4 molecules can establish downstream 
signaling if the receptors are arranged in a symmetrical crosslinked complex bound by 
Spätzle.  Though receptor crosslinking is a fundamental event in signal transduction, it 
is probable that the process of activation involves a series of conformational changes in 
the receptor (Weber, Moncrieffe et al. 2005).   
Studies have shown that the full-length Drosophila Toll ectodomain can form 
unstable dimers in solution in the absence of the ligand Spätzle, although there is no 
evidence to suggest that the receptor when bound to the membrane is expressed as a 
stable pre-formed dimer.  Conversely, truncations at the N-terminus of the receptor 
allow the formation of a stable dimeric complex in solution and causes constitutive 
activation of signaling cascades, indicating that sequences in the N-terminal region of 
the ectodomain mediate receptor-receptor interactions (Winans and Hashimoto 1995; 
Medzhitov, Preston-Hurlburt et al. 1997).  This also indicates that there is steric 
hindrance in Toll caused by the N-terminal region of the ectodomain which prevents 
self-association of the receptors and that binding of Spätzle relieves this constraint.  
Therefore, the N-terminal region of the Toll ectodomain seems to function as an auto-
inhibitor and may provide a structural hindrance that prevents unregulated dimerization 
of the receptor (Hu, Yagi et al. 2004).  The importance of the juxtamembrane region is 
highlighted by findings showing that point mutations in the cysteine residues of the C-
terminal capping structure of the receptor cause constitutive activation of Toll, 
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indicating that the structural integrity of these structures is required for activation 
inhibition (Schneider, Hudson et al. 1991).  Weber et al have demonstrated through 
deletion mapping experiments of the Drosophila Toll ectodomain that the binding sites 
for Spätzle are located in the N-terminal block of LRRs and that the initial ligand-
induced dimerization and the subsequent receptor-receptor interaction are not directly 
coupled (Weber, Moncrieffe et al. 2005).   
The mechanism of Spätzle-Toll binding involves two non-equivalent binding 
events.  The first step, which generates a complex of one ectodomain and one dimeric 
Spätzle molecule, has a higher binding affinity than the second step, which forms the 
signaling-competent receptor-ligand-receptor complex (Weber, Moncrieffe et al. 2005).  
This indicates that the first binding event reduces the affinity for the second binding 
event, indicating that Toll activation involves negative cooperativity.  Negative 
cooperativity is caused by structural changes in the receptor that are induced in the 
binding site for the ligand (in this case Spätzle) as a consequence of the first binding 
event, such that the ligand does not bind as efficiently to the second receptor molecule 
(Figure 1.4).   
 
1.2.2 Discovery of Toll-like Receptors 
The involvement of Drosophila Toll in mediating innate immune responses 
ultimately led to the discovery of sequence homology between the cytoplasmic domains 
of Drosophila Toll and human IL-1 receptor (IL-1R) and eventually to the discovery of 
other Toll-like receptors in vertebrates (Gay, Packman et al. 1991; Rock, Hardiman et 
al. 1998).  The first human homologue of Drosophila Toll to be characterized was  
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Figure 1.4.  Toll activation by Spätzle.  Activation of Toll is mediated through a two-
step reaction.  The first binding event, the formation of a ligand-bound monomer, occurs 
with high affinity.  The second stage of Toll activation, binding of the Toll-ligand 
monomer by a ligand-free monomer, occurs with lower affinity, representing negative 
cooperativity of activation.  Initially, unbound Toll preformed dimers exist in 
equilibrium with monomeric Toll.  Binding of the ligand Spätzle to one Toll receptor 
causes the receptor to switch to an active form.  Ligand binding reduces the affinity of 
the second binding event.  Another Toll receptor binds the active receptor and a signal is 
transmitted (Weber, Moncrieffe et al. 2005). 
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TLR4.  It was found that the gene for TLR4 was localized to the same region to which 
the Lps locus (endotoxin unresponsive gene locus) is mapped.  Lipopolysaccharide 
(LPS) plays an important role in sepsis.  During sepsis, hyperactive responses result in 
excessive proinflammatory responses, ultimately leading to tissue injury and cell death.  
This knowledge led to experiments examining the role of TLR4 in LPS responsiveness  
in which  TLR4-/- mice were created using homologous recombination to replace the 
transmembrane and cytoplasmic regions of the receptor (Hoshino, Takeuchi et al. 1999).  
While wild-type macrophage cells responded normally to LPS stimulation with 
increased levels of tumor necrosis factor α (TNFα) production, TLR4-/- mice showed no 
TNFα production.  Cells from C3H/HeJ mice (LPS-unresponsive) also fail to induce 
inflammatory cytokines, including TNFα, IL-1 and IL-6 and B cells from these mice do 
not proliferate in response to LPS exposure.  Hoshino and coworkers generated mice 
lacking TLR4, and found that cells from these mice did not respond to LPS (Hoshino, 
Takeuchi et al. 1999).  Due to the fact that the cells of TLR4-/- mice and LPS-
unresponsive C3H/HeJ mice responded similarly, the sequence of the TLR4 gene of 
C3H/HeJ mice was examined.  Sequence comparison between the TLR4 gene of LPS-
responsive C3H/HeN mice and that of C3H/HeJ mice showed a point mutation in the 
cytoplasmic region of TLR4, a proline to histidine mutation at position 712, accounted 
for the difference in responsiveness to LPS.  This was confirmed with NF-κB activation 
experiments where cells from C3H/HeJ mice stimulated with LPS showed reduced 
induction of NF-κB (Hoshino, Takeuchi et al. 1999; Arbour, Lorenz et al. 2000).  These 
results demonstrated conclusively that TLR4 was in fact required for responsiveness to 
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LPS and that defects in TLR4 lead to abnormalities in responses to LPS-mediated 
immune stimulation. 
 
1.2.2.1 Members of the Toll-like Receptor Family 
The TLR family displays diversity between species in regards to expression and 
function: TLRs 1 through 9 are conserved both in mice and humans, yet TLR10 is 
present only in humans and TLR11 is functional only in mice.  TLR8, though expressed 
in mice, has been shown to be non-functional.  Here a brief description is provided for 
each of the TLRs and known information for their associated PAMPs. 
 
TLR1, TLR2 and TLR6:   
While LPS was originally considered to be the ligand for TLR2, Wetzler and 
coworkers subsequently demonstrated that contaminating bacterial lipoprotein in the 
LPS preparations, rather than the LPS itself, resulted in TLR2 activation (Wetzler 2003).  
A wide range of ligands are now known to bind TLR2, including Gram-positive 
peptidoglycan (Takeuchi, Hoshino et al. 1999), lipoarabinomannan from mycobacterial 
species (Means, Wang et al. 1999; Underhill, Ozinsky et al. 1999), Trypanosoma cruzi 
glycosylphosphatidylinositol (Campos, Almeida et al. 2001) and phenol-soluble 
modulin from Staphylococcus epidermidis (Hajjar, O'Mahony et al. 2001).   
 The ability of TLR2 to recognize such a broad range of ligands results from 
cooperation with other TLRs, specifically TLR1 (triacyl lipoproteins) or TLR6 (diacyl 
lipoproteins), through dimerization (Ozinsky, Underhill et al. 2000; Takeuchi and Akira 
2001).  For example, while the TLR2/TLR1 heterodimer recognizes a wide variety of 
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lipoproteins, the TLR2/TLR6 heterodimer recognizes only diacylated lipoproteins 
(Takeuchi and Akira 2001; Takeuchi and Akira 2002; Wetzler 2003).  
Heterodimerization of TLRs increases the range of PAMPs which are recognized by the 
receptors. 
 
TLR4: 
 The first identified TLR, TLR4, remains the best characterized of the TLRs.  
LPS, the natural ligand for TLR4, activates the innate immune system leading to the 
production of numerous proinflammatory mediators, such as TNFα, IL-1 and IL-6 
(Medzhitov, Preston-Hurlburt et al. 1997; Akira and Takeda 2004).  
 The recognition of LPS by TLR4 requires several accessory proteins and the 
formation of a complex between several soluble, membrane-linked molecules, including 
CD14 and MD-2, and TLR4 (West, Koblansky et al. 2006).  LPS is first bound to a 
serum protein (LPS-binding protein), and the LPS monomer is transferred to CD14, a 
high-affinity LPS LRR receptor.  CD14 is then proposed to transfer LPS to the TLR4-
accessory protein complex at the cell membrane (Mathison, Tobias et al. 1992; Ulevitch 
and Tobias 1999).  This demonstrates that, while there may not be a direct interaction 
between receptor and ligand, accessory proteins play important roles in ligand 
recognition. 
 Though LPS is the best-characterized ligand for TLR4, this receptor is also 
suggested to play a role in the recognition of heat shock protein 60 (hsp60), and 
lipoteichoic acid (LTA) which is the ligand for TLR2.  
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  TLR5:
 TLR5 is involved in recognition of flagellin, which is the principal component of 
flagella from both Gram-negative and Gram-positive bacteria (Hayashi, Smith et al. 
2001).  Flagellin is proteinous and does not contain atypical features, such as post-
translational modifications, and shares similarities to host proteins.  This may potentially 
eliminate recognition by the innate immune system. 
 The recognition of bacterial flagellin by TLR5 relies on the conserved, central 
core structure of flagellin which is necessary for protofilament assembly and bacterial 
motility (Smith, Andersen-Nissen et al. 2003).  This recognition site is proposed to be 
highly conserved sequences at the amino- and carboxy-termini within the central core of 
flagellin (Samatey, Imada et al. 2001).  A binding site for flagellin on the ectodomain of 
TLR5 proposed to be located between residues 386-407, as it has been shown that 
mutants lacking this domain are unable to interact with flagellin in vitro (Mizel, West et 
al. 2003). 
 
 TLR3, TLR7, TLR8 and TLR9:
 TLRs 3, 7, 8 and 9 are grouped together because they are unified by both having 
nucleic acid PAMPs as well as an intracellular localization.  These PAMPs, both DNA 
and RNA, are distinguished from other PAMPs in that they more closely resemble host 
molecules.  In contrast to the cell surface-localized TLRs described, this subset of TLRs 
is localized to intracellular organelles.  The intracellular localization of the nucleic acid-
activated TLR subfamily is considered to be a safety mechanism to prevent recognition 
 25
of self nucleic acids, while maintaining recognition of non-self nucleic acids (Akira, 
Uematsu et al. 2006). 
 
 TLR3:   
 Cultured cells expressing TLR3 are responsive to purified dsRNA and 
polyinosinic-polycytidylic acid (poly I:C) whereas TLR3-/- mice display impaired 
responses to these ligands (Akira and Takeda 2004).  Upon activation, TLR3 induces 
NF-κB activation and IFN regulatory factor (IRF) 3, leading to the production of 
antiviral molecules such as type I IFN (Alexopoulou, Holt et al. 2001).   
 Though the recognition of dsRNA by TLR3 suggests a role for the receptor in 
antiviral immunity, it has been demonstrated that TLR3 is not required for induction of 
type I IFN during viral infection.  Edelmann and his group have demonstrated that 
TLR3-/- mice display only minor increases in susceptibility to many viral infections 
(Edelmann, Richardson-Burns et al. 2004), suggesting that other PRRs may be involved 
in recognition of dsRNA. 
 
 TLR7/8:
 TLRs 7 and 8 are homologous receptors and recognize PAMPs in a species-
specific manner.  Murine TLR7 and human TLR8 recognize virally-derived guanosine- 
or uridine-rich single-stranded RNA (ssRNA) (Heil, Ahmad-Nejad et al. 2003; Diebold, 
Kaisho et al. 2004).  Both receptors are also responsive to synthetic antiviral 
imidazoquinoline compounds as well as some guanine nucleotide analogues (Heil, 
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Ahmad-Nejad et al. 2003; Diebold, Kaisho et al. 2004).  Though murine TLR8 is 
expressed in cultured cells, it appears to be non-functional (Akira, Uematsu et al. 2006). 
 As cells expressing these receptors are responsive to self and non-self ssRNA 
molecules (Hemmi, Kaisho et al. 2002; Heil, Ahmad-Nejad et al. 2003; Diebold, Kaisho 
et al. 2004), it is likely that the endosomal localization of these receptors acts as a safety 
mechanism to reduce the chances of interaction with self nucleic acids.  Extracellular 
RNAses also act as endogenous safeguards against such an event (Akira, Uematsu et al. 
2006).  Though expression of these receptors confers responsiveness to ssRNA of both 
host and pathogen origin, it has been demonstrated that RNA of host origin is 
significantly less stimulatory than bacterial or viral RNA, suggesting a host modification 
strategy to distinguish self-RNA from non-self RNA (Kariko, Buckstein et al. 2005).  
The two main differences between ‘self’ and ‘non-self’ RNA are the addition of a 5’ 
methyl cap as well as the addition of a 3’ poly (A) tail on eukaryotic RNA (Nelson and 
Cox 2005).  It is possible that the host modification strategy to distinguish self from 
non-self is the modification of the 3’ and 5’ ends of the RNA, although this has not been 
proven. 
 
 TLR9:
 TLR9 is a unique member of the TLR family, in that it is the only receptor which 
responds to prokaryotic and viral DNA.  This recognition is defined by unmethylated 
cytosine-phosphate-guanosine (CpG) dinucleotides within a particular base context, and 
it is known that TLR9-/- mice are unresponsive to challenge with CpG-DNA (Hemmi, 
Takeuchi et al. 2000).  In host genetic material CpG-DNA is highly modified by 
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methylation and suppressed in frequency.  This, in addition to the intracellular 
localization of the receptor, reduces the potential of TLR9 to be activated by 
endogenous genomic DNA. 
 Cellular patterns of TLR9 expression differ between species.  In humans, TLR9 
is expressed primarily in B cells and plasmacytoid dendritic cells (pDCs) of the immune 
system but reports also suggest that it is expressed in activated neutrophils and 
pulmonary epithelial cells (Krieg 2006).  In contrast, murine TLR9 is expressed in 
monocytes and myeloid dendritic cells, in addition to B cells and pDCs (Iwasaki and 
Medzhitov 2004).  As a consequence of this difference in TLR9 expression, it is difficult 
to make predictions regarding TLR9-mediated responses based on extrapolation of 
results from different species (Krieg 2006).  Results obtained from experiments in 
murine cells, for example, are not necessarily an indicator of what responses may be 
generated in human cells. 
 In addition to bacterial DNA, TLR9 is activated by viral DNA sequences 
containing unmethylated CpG sequences.  The genomes of DNA viruses, such as herpes 
simplex viruses 1 and 2 (HSV1 and HSV2) and murine cytomegalovirus, are rich in 
hypomethylated CpG motifs.  Activation of TLR9 by viral CpG-DNA results in the 
induction of inflammatory cytokines and type I IFN secretion in a TLR9-dependent 
manner (Lund, Sato et al. 2003; Krug, Luker et al. 2004; Tabeta, Georgel et al. 2004). 
 Although much is known about the ligands and signaling pathways of TLRs 1 
through 9 and 11, the biological roles of TLRs 10, 12 and 13 remain unclear, as their 
expression patterns, ligands and modes of signaling have yet to be defined (West, 
Koblansky et al. 2006). 
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1.2.3 Structure of Toll-like Receptors 
1.2.3.1 Ligand-Binding Domains 
TLRs contain extracellular LRRs which are responsible for pathogen 
recognition.  The transmembrane domain, as well as cytoplasmic TIR domains, are 
required for initiating intracellular signaling (Akira 2003).  For all TLRs, the ligand 
binding domains consists primarily of a repeating pattern of the LRR motif (Bell, 
Mullen et al. 2003).  This motif is present in a large number of eukaryotic proteins of  
diverse function, typically sharing the unifying characteristic of involvement in 
recognition and interaction processes (Kobe and Kajava 2001).  Indeed the primary 
function of the LRR motif appears to be in providing an adaptable structural matrix for 
biomolecular interactions, the versatility of which is best exemplified by the vast and 
structurally diverse ligands recognized by different TLRs. 
The LRRs of the TLR ectodomains contain a motif that consists of a twenty-
four-residue repeat; xL2xxL5xL7xxN10xφxxφxxxxF20xxL23x, where x represents any 
amino acid and φ represents necessary hydophobic residues (Ile, Val, Met, Phe).  F is a 
conserved phenylalanine, which is frequently replaced with other hydrophobic residues 
and N10 is a conserved asparagine which is often replaced with cysteine, serine or 
threonine (Bell, Mullen et al. 2003).  The LRR is a structural motif that folds in to a 
horseshoe structure and is composed of repeating twenty to twenty-nine amino acid 
stretches that are rich in leucine, a hydrophobic amino acid (Kobe and Kajava 2001).  
Each repeating unit has β-strand-turn-α-helix structure and the surface between the 
helices and sheets is the hydrophobic core of the protein, which is tightly packed with 
leucine residues (Choe, Kelker et al. 2005).   
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 It has been shown that the ectodomains of the receptors are crucial for TLR-
ligand interaction.  A nucleotide polymorphism in TLR9, P99L in LRR2, is said to 
affect function of the receptor (Schröeder and Schumann 2005).  Truncation studies of 
TLR5 have shown that the flagellin binding site is located between residues 386 and 407 
on LRR14 (Mizel, West et al. 2003).  A mutation in TLR4, D299G, inactivates TLR4 
and leads to hyporesponsiveness to LPS (Arbour, Lorenz et al. 2000).  Thus, it appears 
as though the ectodomains, containing the LRRs, are important in ligand binging and 
recognition. 
All TLR ectodomains contain non-LRR sequences at their N- and C-termini.  
The N-terminal residues form a β hairpin, with a disulfide bond connecting the 
β strands.  This type of structure stabilizes the LRR solenoid by capping the 
hydrophobic core of the first LRR.  In contrast to the N-terminal caps, which are 
variable among TLRs, the C-terminal regions contain a highly conserved consensus 
sequence which is also stabilized by disulfide linkages (Huizinga, Tsuji et al. 2002). 
 
1.2.3.2 Structural Determination of Toll-like Receptors 
To date no structural information is available for TLR9 to offer insights into 
ligand binding.  However, crystallographic determinations have been performed for 
human TLR3, which has a degree of sequence identity to human TLR9 [25% identity 
over the whole protein based on a Blast2 sequence alignment of human TLR3 (U88879) 
and human TLR9 (AF245704), NCBI] and also binds unmethylated pathogenic nucleic 
acids within acidic endosomal compartments (Bell, Botos et al. 2005; Choe, Kelker et 
al. 2005).  Human TLR3 is activated by double stranded RNA (dsRNA) associated with 
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viral infection, endogenous cellular mRNA, and sequence-independent small interfering 
RNAs. 
The three dimensional crystal structure of the TLR3 ectodomain, as determined 
by Choe and coworkers, is a large, horseshoe-shaped assembly consisting of twenty-
three LRRs that adopt a right-handed solenoid structure (Choe, Kelker et al. 2005).  The 
concave (inner) surface is formed from twenty-five parallel β strands, twenty-three from 
LRRs and one each from the N- and C-terminal cap regions that assemble into a highly 
curved, continuous β sheet that spans 270o of an arc.  The convex (outer) surface 
contains more diverse secondary structure elements, including a variety of different 
length of loops, four α helices, seven 310 helices, and two β strands.   
Fifteen potential N-linked glycosylation sites are located in the ectodomain of 
TLR3 (Blom, Sicheritz-Ponten et al. 2004).  When the locations of the predicted N-
glycosylation sites of the TLR3 ectodomain are examined, they are predominantly 
located on the concave surface of the receptor.  This glycosylation pattern is not unique 
to TLR3, as other members of the TLR family are predicted to be similarly glycosylated 
(Weber, Morse et al. 2004).  This is unexpected because the concave surface of the 
TLR3 ecotdomain was predicted to be the ligand-binding site, as it has been shown to be 
for many other LRR-containing proteins.  For example, ribonuclease inhibitor, 
internalin, and platelet glycoprotein-IBα have been shown to preferentially bind ligands 
in the cavity created by the β-sheet (Bell, Mullen et al. 2003).  The combined presence 
of glycosylation and the predominant negative charge of the concave surface make it an 
unlikely site for binding dsRNA.  Instead, Choe proposes that the putative ligand  
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binding site for dsRNA is located on the glycosylation-free face of TLR3, the convex 
side of a dimerized structure (Figure 1.5).  
In contrast to the model proposed by Choe and Bell, a binding groove for 
dsRNA within an inner cavity of a TLR3 monomer (Bell, Botos et al. 2005).  The 
overall structure suggested is that of a large curved solenoid.  The concave inner surface 
consists of a large parallel β sheet with each β strand roughly perpendicular to the 
solenoid axis and linked to the next strand by loop structure.  The consensus 
hydrophobic residues point toward the interior of the molecule, forming a hydrophobic 
core.  Although glycans, which may affect and direct ligand binding by occlusion, were 
found on the concave surface of the TLR3 ectodomain, two sulfate ions from the 
crystallization medium were observed to be bound to the concave surface of the TLR3 
ectodomain which would suggest that sulfate ions can mimic the phosphate of the 
nucleotide backbone and provide clues to the potential binding site.   
The horseshoe-shaped core provides a large surface area for ligand interaction 
and recognition.  The extensive β sheet on the concave surface of TLR3 ectodomain 
forms a stable platform upon which loops, insertions, and short helices are anchored.  
These irregular features are highly conserved among mammalian TLR3 orthologs and 
apparently evolved over time to facilitate recognition of pathogens that pose a specific 
threat to the host.  The differential glycosylation among the TLRs could control access  
to specific interaction surfaces.  A character of the TLR structure is the large spatial 
separation of many of the features on the protein core, raising the possibility that each 
TLR paralog might recognize several different ligands at different sites, thus helping to  
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 Figure 1.5.  Crystal structure of the TLR3 ectodomain.  A)  Structure of the TLR3 
ectodomain as described by Bell et al. (Bell, Botos et al. 2005).  B) Overall ribbon 
structure of the TLR3 ectodomain as described by Choe et al. (Choe, Kelker et al. 
2005). 
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explain the ability of TLRs to recognize a variety of structurally unrelated ligands 
(Takeda, Kaisho et al. 2003). 
Collectively, rather than resolving the structural mechanisms of nucleic acid 
recognition, these structures add further controversy by proposing two conflicting 
models of ligand binding; Bell hypothesized a binding groove for double-stranded RNA 
within an inner cavity of a TLR3 monomer (Bell, Botos et al. 2005) while Choe 
proposed the convex side of a dimerized structure as the ligand-binding region (Choe, 
Kelker et al. 2005).   
 
1.2.3.3 TIR Domain 
The cytoplasmic portion of TLRs is very similar to that of the interleukin-1 
receptor (IL-1R) family.  The C-terminal regions of TLRs contain a conserved stretch of 
approximately 200 amino acids which is required for binding of MyD88 and subsequent 
signal transmission.  This is referred to as the Toll/Interleukin-1 receptor (TIR) domain.  
Conservation of the TIR domain throughout the TLR family suggests a conserved 
signaling scheme which would indicate an evolutionarily conserved immune response in 
insects and vertebrates (Gay and Keith 1991).  Indeed, the signaling pathways of the 
TLRs are homologous to that of the mammalian IL-1R family as a consequence of this 
conserved cytoplasmic TIR domains found in both receptor families (Takeshita, Gursel 
et al. 2004).   
The TIR domain is required for homotypic protein-protein interactions.  A point 
mutation in the Tlr4 gene in the TIR domain of TLR4 abolishes responsiveness to LPS, 
and an equivalent mutation in the TIR domain of TLR2 abolishes responsiveness to 
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yeast and Gram-positive bacteria (Poltorack, He et al. 1998; Underhill, Ozinsky et al. 
1999).  Xu and colleagues have elucidated the crystal structures of the TIR domains of 
human TLRs 1 and 2 (Xu, Tao et al. 2000).  The structures reveal that the TIR domain is 
made up of a central five-stranded parallel β-sheet surrounded by five helices.  The core 
of the TIR domain starts at an (F/Y)DA amino acid motif and ends eight residues C-
terminal to a conserved phenylalanine or tryptophan residue, and most of the conserved 
residues of the TIR domain lie within this hydrophobic core.  There are insertions and 
deletions within the loop regions of TIR domains within the TLRs, which accounts for 
the differences in size of the TIR domains which range typically from 135 to 160 amino 
acids.  These loop regions contain many conserved residues which are critical for signal 
transduction, as mutations in these conserved patches have been shown to block signal 
transduction (Xu, Tao et al. 2000). 
Signaling pathways activated via the TIR domain trigger the activation of 
downstream kinases, and transcription factors such as NF-κB, and the adaptor protein 
MyD88.  MyD88, critical for induction of NF-κB following TLR activation, is a 
cytoplasmic effector protein which also contains a TIR domain (Bowie and O'Neill 
2000).  The presence of a C-terminal TIR domain in the effector enables interactions 
with the TIR domains of the TLRs.  As a testament to the central role that MyD88 plays 
in MyD88-dependent TLR-mediated innate immune response, MyD88-deficient mice 
do not respond to peptidoglycans, flagellin, CpG-DNA or ssRNA (Adachi, Kawai et al. 
1998; Takeda and Akira 2003; Beutler 2005; Yarovinsky, Kanzler et al. 2006).   
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1.2.3.4 Pathways Activated 
Following activation of a Toll-like receptor by its PAMP several outcomes are 
possible.  Cellular responses are observed as immune cells produce signaling factors, 
chemokines and cytokines, which trigger inflammation.  In the case of a bacterial factor, 
the pathogen might be phagocytosed and digested, and its antigens presented to CD4+ T 
cells.  In the case of a viral pathogen, the infected cell may shut off its protein synthesis 
and may undergo programmed cell death (apoptosis).  Immune cells that have detected a 
virus may also release anti-viral factors such as interferons which inhibit viral 
multiplication and modify the body’s immune response.  The discovery of the TLRs 
finally identified the innate immune receptors that were responsible for many of the 
innate immune functions that had been studied for many years.  Interestingly, TLRs 
seem only to be involved in the cytokine production and cellular activation in response 
to microbes, and do not play a significant role in the adhesion and phagocytosis of 
microorganisms. 
MyD88 is the functional homolog of Drosophila Tube in that it is an adaptor 
protein.  Like Tube, MyD88 has a death domain involved in recruitment of the 
downstream serine/threonine kinase (Pelle for Tube, IRAK for MyD88), whereas, in 
contrast to Tube, it has a TIR domain, most likely involved with interactions with IL-
1R/TLR family receptor complexes.  MyD88 has recently been confirmed as having a 
central role in the immune signaling cascades of the IL-1R/TLR family in that MyD88-/- 
mice, the responses to IL-1, IL-18 and LPS are all abrogated (Adachi, Kawai et al. 1998; 
Kawai, Adachi et al. 1999). 
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When activated, TLRs recruit adaptor molecules within the cytoplasm of cells to 
propagate a signal.  Four adaptor molecules are known to be involved in signaling.  
These proteins are MyD88, TIR domain-containing adaptor protein (Tirap, also called 
Mal), TIR domain-containing adaptor protein inducing IFN-β (Trif) and Trif-related 
adaptor molecule (Tram) (Yamamoto, Sato et al. 2002; Yamamoto, Sato et al. 2003; 
Yamamoto, Sato et al. 2003).  The adaptors activate other molecules within the cell, 
including certain protein kinases (IRAK1, IRAK4, TBK1 and IKKi) that amplify the 
signal, and ultimately lead to the induction or suppression of genes that orchestrate the 
inflammatory response.  In all, thousands of genes are activated by TLR signaling and, 
collectively, the TLR family constitutes one of the most powerful and important 
gateways for the modulation of gene expression (Figure 1.6). 
Understanding of the kinases involved in NF-κB activation has increased in 
recent years.  These kinases, IκB kinase (IKK) α and β, exist as part of a larger IKK 
signalsome that contains other scaffold and regulatory proteins.  IKKα and β form a 
core IKK complex together with IKKγ (or NEMO, NF-κB essential modulator), which 
seems to be the minimal requirement for NF-κB activation (Bowie and O'Neill 2000).  
Many upstream kinases have been shown to be capable of activating the IKK complex 
in vitro, including NIK, MEKK1, TAK1, protein kinase Cζ, and MEKK2 (Lee, Hagler 
et al. 1997; Zhao and Lee 1999), which may explain how diverse stimulants can activate 
NF-κB.  In terms of IL-1R/TLR pathways, MEKK1 and NIK are particularly important 
(Muzio, Ni et al. 1997; Kopp, Medzhitov et al. 1999).  Although the different IL- 
1R/TLR family members use similar signaling pathways, there may be subtle 
differences in the adaptor proteins recruited during signaling. 
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Figure 1.6.  Signal transduction associated with TLR9.  Binding of bacterial DNA or 
CpG ODNs promotes activation of TLR9 through dimerization.  The ligand-bound 
dimer recruits MyD88 to the membrane and initiates association with adaptor molecules 
such as IRAK4.  MyD88 activates IRAK4 to phosphorylate IRAK1.  Once 
phosphorylated, IRAK1 recruits TRAF6 to activate TAK1, resulting in activation of the 
MAPK signaling cascades, JNK1 and p38.  TRAF6 also activates the IKKs, which 
phosphorylate IκB.  Phosphorylated IκB dissociates from NF-κB and is degraded.  NF-
κB translocates to the nucleus to induce expression of proinflammatory cytokines.  The 
resulting pattern of gene expression induces several immunomodulator effects including 
cell-mediated immunity, apoptosis as well as direct antimicrobial activity. 
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All TLRs elicit conserved inflammatory pathways, culminating in the activation 
of NF-κB and AP-1.  NF-κB is a dimeric transcription factor that belongs to the Rel-
homology domain-containing protein family, which includes p65/RelA, p50/NF-κB1, 
p52/NF-κB2, RelB and c-Rel (Karin and Greten 2005).  TLR signaling leads to 
activation of several transcription factors, including NF-κB and IRFs, which 
subsequently mediate the induced expression of a variety of immune response genes.  
Each TLR activates similar signaling pathways, but some TLRs trigger specific and  
unique pathways.  This differential induction pattern depends heavily on cytoplasmic 
adaptor molecules that can associate with the intracellular region of TLRs (Akira 2003).
  
1.3 Toll-like Receptor 9 
1.3.1 Discovery of TLR9 
The discovery of Toll in Drosophila lead to the discovery of the TLR family.  
After the characterization of the first mammalian TLR, TLR4, several proteins related to 
TLR4 were identified and named TLRs (Rock, Hardiman et al. 1998).  Prior to a study 
conducted by Hemmi, the ligand for TLR9 was unknown and the receptor had not yet 
been characterized.  At the time only TLRs 1-6 had been identified, and the sequences 
for TLRs 7 and 8 deposited in to GenBank.  Using a BLAST search, Hemm and 
coworkers identified an expressed sequence tag (EST) which had high degree of 
similarity to the previously identified TLRs.  Using the EST as a probe, a full-length 
complementary DNA (cDNA) was isolated from the murine and human cDNA libraries.  
Sequence analysis indicated that these cDNAs contained regions conserved within the 
TLR family, including the LRR and TIR domains.  The gene was designated Tlr9. 
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To determine the biological function of TLR9, analyses of TLR9-deficient 
(TLR9-/-) mice were carried out and revealed that TLR9 is a receptor for a cytosine-
phosphate-guanine (CpG) motif in DNA (Hemmi, Takeuchi et al. 2000) as TLR9-/- mice 
did not show any response to CpG DNA, including cell proliferation and production of 
inflammatory cytokines.  In addition to bacterial CpG DNA, TLR9 has been shown to 
recognize viral-derived CpG DNA in plasmacytoid dendritic cells (Lund, Sato et al. 
2003; Krug, Luker et al. 2004).  TLR9-mutant mice have also been shown to be 
susceptible to murine cytomegalovirus (MCMV) infection (Tabeta, Georgel et al. 2004), 
indicating that TLR9 is implicated in the recognition of this virus. 
 
1.3.2 Bacterial DNA as a PAMP 
While attempting to identify the antitumor components of Bacillus Calmette-
Guerin extracts, Tokunaga and colleagues established that bacterial genomic DNA may 
account for the observed immune stimulation (Tokunaga, Yamamoto et al. 1984).  
Messina later demonstrated that poly-(dC, dG) from purified bacterial DNA was able to 
induce B cell proliferation, while vertebrate DNA did not have this activity (Messina, 
Gilkeson et al. 1991).  In a subsequent report by Krieg, it was reported that the 
mitogenic activity of bacterial DNA to B cells was due to the presence of unmethylated 
CpG dinucleotides in a particular base sequence termed the CpG motif (Krieg, Yi et al. 
1995).  In agreement with previous studies, methylation of CpG sequences removed the 
immunostimulatory activity. 
Different genera of bacteria have differences in the C/G content of their DNA.  
Since TLR9 recognizes CG-containing DNA motifs, it can be assumed that DNA from 
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different bacteria should vary in their capacity to activate TLR9.  Dalpke et al observed 
that bacterial DNA from different species do, in fact, differ in their potential to stimulate 
TLR9 (Dalpke, Frank et al. 2006) and that the CG content, that is to say the DNA 
sequence, of the bacterial DNA had an effect on the activity of TLR9. 
 
1.3.2.1 CpG Motifs 
Foreign and host DNA appear to be discriminated on the basis of unmethylated 
CpG dinucleotide sequences which are frequent within microbial DNA but largely 
absent from host cell genetic material (Bird 1986; Krieg, Yi et al. 1995; Krieg 2002).  
The immunostimulatory activity of the CpG motif is found in non-self DNA, while 
mammalian cells ignore high concentrations of their own (self) DNA.  Bacterial DNA 
contains unmethylated CpG motifs, which give the DNA its immunostimulatory 
activity.  In vertebrates, the frequency of CpG motifs is greatly reduced, approximately 
1/5 of the frequency observed in bacterial DNA, and the cytosine residues of the motifs 
are highly methylated, decreasing, or eliminating, the immunostimulatory activity (Bird 
1986; Deng, Nilsson et al. 1999; Takeda and Akira 2005).  CpG DNA has been shown 
to be an excellent immune adjuvant in various models of murine disease (Weiner, Liu et 
al. 1997; Davis, Weeranta et al. 1998).  CpG-induced activation of innate immune 
responses protects against lethal challenge with a variety of pathogens, and has 
therapeutic activity in murine models of cancer and allergy (Krieg 2002).  CpG ODNs 
also enhance the development of acquired immune responses for prophylactic and 
therapeutic vaccination. 
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1.3.2.2 Higher Order Species-Specific Activation 
In addition to the CpG dinucleotide, TLRs also recognize higher order sequences 
around the dinucleotide.  These sequences appear to be recognized in a species-specific 
fashion.  Mouse TLR9 is most responsive when the CpG motif is flanked by purine 
residues on the 5’ side and pyrimidine residues on the 3’ side; GACGTT (Yu, 
Kandimalla et al. 2003); human TLR9 by GTCGTT or TTCGTT sequences (Bauer, 
Kirschning et al. 2001).  Therefore, the specificity of TLR9-dependent activation of the 
immune system may involve recognition of higher order motifs beyond the CpG 
dinucleotide.   
Responsiveness to immunostimulatory CpG DNA correlated with human TLR9 
expression in human immune cells (Bauer, Kirschning et al. 2001).  Expression of TLR9 
in human non-responder cells results in these cells becoming responsive to 
immunostimulatory CpG DNA, indicating that the specificity represents preferential 
binding by TLR9.  Transfection of either human or murine TLR9 conferred 
responsiveness, yet required species-specific CpG DNA motifs for initiation of signaling 
pathways (Bauer, Kirschning et al. 2001).  Non-optimal ODNs gave delayed and less 
sustained activation of signaling pathways (Roberts, Sweet et al. 2005).  When the CpG 
dinucleotide is inverted to GC in the ODNs, some residual activity was retained in a 
species-specific, TLR9-dependent manner (Rutz, Metzger et al. 2004). 
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1.3.3 TLR Localization 
1.3.3.1 Intracellular Localization of Nucleic Acid-binding TLRs 
TLR3, TLR7, TLR8 and TLR9 have evolved to recognize the nucleic acids of 
bacteria and viruses.  However, nucleic acids are also endogenous to mammalian cells, 
and it is important that these molecules not be recognized as “non-self” to avoid the 
activation of inflammatory responses.  A way that “self”-nucleic acids may be prevented 
from activating TLRs is through their physical separation from the nucleic acid-binding 
TLRs.  The ligand-binding domains of TLRs are situated either on the cell surface or in 
intracellular compartments.  Nucleic acid-binding TLRs are located intracellularly, 
rather than at the cell surface.  The sequestration of the nucleic acid-binding TLRs to 
intracellular locations may reflect a strategy to avoid inappropriate activation by self 
molecules.  Interestingly, the ability of these receptors to bind their ligands may require 
non-neutral pHs, such as the acidic environment that exists within the endosomes (Watts 
2004; Bell, Askins et al. 2006; Gibbard, Morley et al. 2006). 
Studies have shown that phagocytosed antigens do not enter the appropriate 
intracellular location in the absence of TLR ligands, indicating that cells of the immune 
system that are not activated by TLRs do not process and present antigen (Blander and 
Medzhitov 2004).  This also suggests that phagosomal maturation is regulated by TLRs.  
Co-localization of the TLR signal and the antigen may be a crucial factor.  Another 
study focused on recognition of cytosolic nucleic acids, showing that while wild-type 
receptors were not activated by host nucleic acids, chimeric receptors improperly 
localized at the cell surface, rather than in intracellular compartments, were responsive 
to host nucleic acids (Heil, Ahmad-Nejad et al. 2003; Barton, Kagan et al. 2006).   
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TLRs 3, 7, 8 and 9 are all closely related in sequence (Figure 1.7) and have the same 
conserved features, such as a cysteine-rich insert in LRR8 (Bell, Mullen et al. 2003; 
Matsushima, Tanaka et al. 2007), indicating that they might have related mechanisms 
for the recognition of nucleic acids and nucleotide analogues.  These TLRs are localized 
to intracellular compartments rather than at the cell surface, and it has been 
demonstrated that this subcellular localization is required for their function (Lee, 
Chuang et al. 2003; Latz, Schoenemeyer et al. 2004).  Medzhitov showed that the 
subcellular localization is important for specificity and for the discrimination of self 
from non-self nucleic acids (Medzhitov and Janeway Jr. 2000; Barton, Kagan et al. 
2006).  They showed that the intracellular localization of TLR9 is specified by the 
transmembrane α-helix and that a chimeric receptor composed of the TLR9 ectodomain 
and the TLR4 transmembrane and cytoplasmic domains is trafficked to the cell surface, 
indicating that the transmembrane domain is required for localization.  These hybrids 
are able to signal in response to exogenous self nucleic acids, whereas native TLR9 
responds only to viral or bacterial CpG-containing DNA.   
 
1.3.3.2 Trafficking and Requirement for Acidification 
Many experiments have been performed to determine whether CpG DNA moves 
to the same compartment in which TLR9 is expressed, or whether TLR9 moves to 
where the ligand, CpG DNA, is located (Latz, Schoenemeyer et al. 2004; Yasuda, Yu et 
al. 2005).  It has been well-established that unmethylated CpG-containing plasmids 
induce activation of NF-κB in a TLR9-dependent manner (Bauer, Kirschning et al. 
2001).  This activation is highly specific because methylated CpG-containing plasmids,
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 Figure 1.7.  Protein sequence alignment of human TLRs 3, 7, 8 and 9.  Colored 
regions represent exact base matches.  Using TLR3 (GenBank ascension number 
U88879) as a reference: TLR7 (AF240467) has 26% exact base matches, TLR8 
(AF245703) has 26% and TLR9 (AF245704) has 24% exact base matches.   
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as well as methylated CpG-ODNs, are ineffective in activating NF-κB.  It is also 
established that chloroquine, an agent which blocks endosomal maturation, blocks, at 
least in part, cellular activation by the unmethylated CpG-containing plasmid or by 
CpG-ODN, suggesting that endosomal maturation may be required for TLR9 signaling 
(Hartmann and Krieg 1999).  The LPS transduction pathway via TLR4, which can use 
the same adaptor proteins as TLR9, was not inhibited by chloroquine and derived 
compounds (Yi, Tuetken et al. 1998), which suggests that the activation of the signal 
transduction pathway induced by plasmid DNA requires its internalization and the 
acidification of the endosome.  
It has been established that in the resting cell, most of the cellular TLR9 resides 
in the endoplasmic reticulum (ER) (Leifer, Kennedy et al. 2004).  How TLR9 gains 
access to internalized CpG ligands is not well-understood, but it is known that TLR9 can 
be detected in lysosomes after stimulation with CpG DNA (Latz, Schoenemeyer et al. 
2004).  It has been shown that TLR9 is retained in the ER prior to CpG DNA exposure 
(Latz, Schoenemeyer et al. 2004; Leifer, Kennedy et al. 2004), and it has been proposed 
that TLR9 gains access to endosomes containing CpG DNA by direct fusion of the 
endosome with the ER.  
The fact that all of the intracellular TLRs identified share specificity for nucleic 
acids suggests that this localization is related to the recognition of this class of ligands.  
Nucleic acid ligands may need to be modified in acidified compartments before they can 
be recognized.  Also, intracellular compartments may serve to concentrate ligands in 
such a way as to reach the threshold required to activate the receptor.  The degradative 
environment of mature endosomes and lysosomes may break down bacteria or viruses, 
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releasing nucleic acids for the recognition by TLRs.  Finally, the intracellular 
localization of TLRs 3, 7, 8 and 9 may help distinguish the sources of nucleic acids.  
This arises from the issue that, in contrast to most TLR ligands, nucleic acids can be 
either foreign or self (Leadbetter, Rifkin et al. 2002; Viglianti, Lau et al. 2003).  
Mammalian DNA, for example, can stimulate TLR9 in some situations (Barton, Kagan 
et al. 2006).  Therefore, a mechanism must exist to ensure that TLRs involved in nucleic 
acid recognition can discriminate between foreign and self nucleic acid. 
 
1.3.4 ODNs as TLR9 Ligands 
1.3.4.1 ODN Classes and Actions 
The immunostimulatory action of bacterial DNA can be mimicked with short 
single-stranded oligodeoxynucleotides (ODNs).  These ODNs have considerable 
advantages as therapeutic TLR9 agonists as a result of their defined sequences and 
structures, low cost and chemical stability.  To achieve greater biological stability 
through nuclease resistance, the majority of TLR9 investigations utilize 
phosphorothioate-modified (PTO) ODNs in which one of the non-bridging backbone 
oxygen atoms is replaced with sulfur (Figure 1.8)   
At least three distinct classes of oligonucleotides containing CpG motifs have 
been reported based on their ability to induce different cellular responses (Klinman 
2004) (Table 1.4).  Conventional CpG DNA, B-type CpG DNA, has the potent ability 
to activate B cells and induce cytokine production from macrophages.  B-type CpG 
DNA has multiple CpG motifs, and stabilized by a phosphorothioate backbone (Krieg 
2002).  A-type CpG DNA shows a weaker ability to activate B cells or macrophages but  
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Figure 1.8.  Chemical structure of a phosphorothioate CpG ODN.  A non-bridging 
oxygen atom is replaced with a sulfur atom to differentiate phosphodiester ODNs from 
the modified form (Integrated DNA Technologies, www.idtdna.com). 
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Table 1.4.  Representative sequences, structures and biological actions of the 
different ODN classes.  Adapted from Klinman, DM. 2004 (Klinman 2004). 
 
 
ODN 
Type 
Example 
Structural 
characteristics 
Associated 
activity 
A GGTGCATCGATGCAGGGGGG
PD and PTO backbone 
Single CpG motif 
Poly G tail 
Hairpin forming 
sequences 
Stimulate pDCs 
to release IFN-α 
IFN-α-mediated 
APC maturation 
B TCCATGGACGTTCCTGAGCGTT
PTO backbone 
Multiple CpG motifs 
Maturation of 
pDC and TNF 
production 
B cell 
proliferation 
IL-6 production 
C TCGTCGTTCGAACGACGTTGAT
PTO backbone 
Multiple CpG motifs 
Hairpin forming 
sequences 
Stimulate pDCs 
to release IFN-α 
B cell 
proliferation 
IL-6 production 
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a stronger ability to induce type I IFN production from plasmacytoid dendritic cells.  A-
type CpG DNA contains only a single CpG motif, and the activity requires a mixed 
backbone of phosphodiester-phosphorothioate (Krug, Rothenfusser et al. 2001).  In 
addition, the region around a CpG motif should be palindromic and phosphodiester-
linked, and a poly-G tail should be included at the 3’ end.  C-type CpG DNA exhibits 
type I IFN-inducing, as well as B cell-activating, functions.  It is comprised of a 
phosphorothioate backbone with multiple CpG motifs and a TCG dimer at the 5’ end 
(Marshall, Fearon et al. 2003).  B-type CpG DNA is rapidly transferred and degraded in 
the lysosome, whereas A-type CpG DNA is retained in the endosome of pDCs, together 
with signal-transducing molecules, such as MyD88 and IFN regulatory factor (IRF) 7 
for long periods.  If B-type CpG DNA is modified by cationic lipids to be retained in the 
endosome, it can induce type I IFN production, even from conventional DCs.  Through 
G tetrad formation of poly-G tail, A-type CpG DNA tends to self-assemble in to a 
nanoparticle, which resembles the viral structure (Kerkmann, Costa et al. 2005).  This 
particular structure contributes to intracellular localization of A-type CpG DNA.  
Structurally, the three classes of ODNs differ in the number and positioning of CpG 
motifs, as well as in the presence of backbone modification and the extent to which the 
backbone is modified (Krieg 2002).  When these ODN sequences were subject to 
computational secondary structure prediction analysis, it was observed that many of the 
ODNs have the potential to adopt higher order structures based upon the formation of 
hairpin structures (Verthelyi, Ishii et al. 2001).  It is postulated that the observed ODN 
class-specific differences in immunostimulation may be dictated by the different fit 
between each class of ODN and the TLR9 molecule.  For instance, the binding of each 
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class of CpG ODN and the TLR9 molecule may trigger different conformational 
changes in the receptor and/or promote recruitment of unique co-signaling adaptor 
molecules or accessory proteins.  Class-specific responses suggest that although all CpG 
ODNs can interact with TLR9, there are likely differences in the mechanisms of 
trafficking, recognition and/or signal transduction induced by each class either due to 
the sequence/structure differences between the ODNs or differences in accessory 
proteins or co-stimulatory molecules that are recruited to the TLR9-ODN complex 
which have not yet been identified. 
 
1.3.4.2 Functional Consequences of the PTO Modification 
PD-ODNs are inherently susceptible to nucleases and as such are rather unstable.  
In order to achieve greater biological stability through nuclease resistance, the majority 
of TLR9 investigations utilize PTO-ODNs.  These ODNs are known to have CpG-
independent side effects including induction of B cell proliferation, splenomegaly, and 
tissue infiltration by mononuclear cells, indicating that the PTO-modified backbone 
does behave independently of CpG, and behaves differently than the unmodified PD 
backbone (Barton, Kagan et al. 2006; Yasuda, Rutz et al. 2006).  While PD-ODNs are 
unstable and have poor cellular permeability, PTO-ODNs are more stable and are taken 
up more efficiently by cells.   
The PTO modification is not a neutral substitution, although it is not yet clear 
how this modification influences the specificity of interaction with TLR9.  PTO-ODNs 
have been described as “sticky” with the tendency to interact with other proteins, 
including other TLRs (Rutz, Metzger et al. 2004).  The interactions with proteins other 
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than TLR9 may account for the ability of PTO-ODNs to exert CpG-independent side 
effects (Khaled, Benimetskaya et al. 1996; Baek, Ha et al. 1997; Monteith, Henry et al. 
1997).  Clearly, TLR9 activation by PTO-ODNs and natural PD-ODNs does in fact 
differ (Kirk and Bazan 2005).  
 
1.3.5 TLR9 as a Therapeutic Target 
1.3.5.1 Uses and Advantages 
The low cost, ease of production and stability of nucleic-acids ligands make 
TLR9 an attractive target for immunotherapeutic intervention.  These nucleic acid 
ligands, particularly CpG-ODNs, have the additional advantage of being one of the most 
selective stimulators of dendritic cells with minimal systemic toxicity (Ioannou, Griebel 
et al. 2003).  The ability for CpG treatment to modulate innate immune responses has 
given rise to a number of therapeutic applications including: 1) priming the innate 
immune system to mediate host protection, 2) as adjuvants to promote induction of 
antigen-specific immune responses, 3) as anti-allergens through establishment of TH1 
responses, 4) in the treatment of a variety of malignancies and 5) for improved 
vaccination efficiency of individuals with poor immune responses (Krieg, Yi et al. 1999; 
Dittmer and Olbrich 2003; Klinman 2004; Lazarczyk, Grzela et al. 2005).   
Therapeutic targeting could be done by: 1) prevention of ligand binding to LRR 
domains of receptors; 2) blocking the interactions between receptors and adaptors in the 
signaling pathways; 3) blocking the enzymes in signaling pathways and; 4) 
immunostimulation with vaccine adjuvants.  There are different signaling events which 
occur after receptor-ligand interaction and it is theoretically possible to design new 
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therapeutics for human immune diseases and inflammatory disorders using knowledge 
of the signaling pathways.  The information regarding the structure of TLR9 and of 
pathways activated could also be used in therapeutic approaches for modulating the 
innate immunity.  In addition to PAMPs, synthetic analogues of PAMPs and fully 
synthetic small molecules could be used as agonist or antagonist ligands of the TLRs.   
 
1.3.5.2 Potential Problems 
Though CpG DNA is one of the most selective stimulators of dendritic cells with 
minimal toxicity, concerns have been raised over the potential for the therapeutic 
application to trigger the development of autoimmune disease.  Studies have shown that 
high doses of bacterial DNA elicit the production of auto-antibodies against double-
stranded DNA in normal mice and accelerate the production of autoimmune antibodies 
in lupus-prone animals (Gilkeson, Ruiz et al. 1993).  CpG-ODNs may also facilitate the 
development of toxic shock by lowering the pathological threshold of LPS tolerance 
(Sparwasser, Miethke et al. 1997).  It has also been demonstrated that ODNs can exhibit 
sequence-independent effects, indicating that the stimulatory capacity of the ODN is due 
to more than the DNA sequence.  While the risks associated with these scenarios are 
low, they emphasize the importance of optimization of TLR9 agonists.  
 
1.3.6 Current Status of Knowledge 
1.3.6.1 Binding of Double-stranded Nucleic Acids 
It has been demonstrated that innate immune responses can be initiated by 
plasmid DNA (Sato, Roman et al. 1996; Roman, Martin-Orozco et al. 1997) and time 
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course experiments verify that plasmids remain intact within the endosomes for 
sufficient time to serve as TLR9 ligands (Bennett, Gabor et al. 1985).  Previous 
investigations have reached opposing conclusions, however, with respect to the ability 
of TLR9 to bind double-stranded DNA.  While a system established by Cornélie 
demonstrated effective binding of plasmids to TLR9 (Cornélie, Hoebke et al. 2004), an 
independent investigation by Rutz et al reported only a weak interaction between TLR9 
and double-stranded ligands, indicating that the immunostimulatory activity of the CpG 
DNA was dependent on the single-stranded character of the molecule (Rutz, Metzger et 
al. 2004).   
Surface plasmon resonance (SPR) has been used to demonstrate the binding of 
CpG DNA by TLR9.  Cornélie and his group were able to show that murine TLR9 binds 
unmethylated CpG-containing plasmid.  The interaction was shown to be sequence-
specific, influenced by the methylation status of the plasmid and lead to activation of the 
NF-κB pathway in TLR9-expressing cells (Cornélie, Hoebke et al. 2004).   
SPR was primarily used to study the physical interaction between murine TLR9 
and a CpG-containing plasmid.  When unmethylated CpG-containing plasmid was 
injected on to the sensor chip, the absorption signal was increased.  This signal was 
enhanced with increasing doses of plasmid, indicating that the unmethylated CpG-
containing plasmid was binding to murine TLR9.  In contrast, methylated CpG-
containing plasmid showed only a marginal increase in signal absorption which was not 
enhanced with increasing doses of plasmid, indicating that the binding was non-specific 
(Cornélie, Hoebke et al. 2004). 
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1.3.6.2 Sequence Specificity 
While cell stimulation assays suggest the preferential ability of CpG ODNs to 
initiate cellular responses, in vitro binding assays have reached contrasting conclusions 
with respect to the ability of TLR9 to bind nucleic acids in a sequence-specific fashion. 
Using SPR to prove that the receptor-ligand interactions were CpG-specific 
competition experiments were performed with plasmids, CpG-ODNs and GpC-ODNs.  
CpG-ODNs were able to inhibit binding of the plasmid to murine TLR9, while the 
inverted GpC-ODN did not inhibit binding of the plasmid.  This indicated that murine 
TLR9 was in fact the receptor for plasmid DNA and that binding of DNA to the receptor 
was dependent on the presence of unmethylated CpG motifs (Cornélie, Hoebke et al. 
2004). 
The results generated with SPR were confirmed with NF-κB activation 
experiments.  Cells were transfected with murine TLR9 as well as a reporter plasmid 
driven by the NF-κB promoter.  Cells were incubated with CpG-ODN or inverted GpC-
ODN.  CpG-ODN dramatically induced activation of NF-κB, whereas the GpC-ODN 
induced activity comparable to that detected when mTLR9 was not expressed.  This 
induction was also dependent on the methylation status of the CpG motif.  
Unmethylated CpG-ODN activated NF-κB, while methylated CpG-ODN did not 
(Cornélie, Hoebke et al. 2004). 
Rutz also used SPR to demonstrate that TLR9 interacts directly and sequence-
specifically with CpG-DNA (Rutz, Metzger et al. 2004).  They also showed that TLR9-
CpG-DNA interaction is blocked by chloroquine and quinacrine, suggesting that both 
compounds act as TLR9 agonists.  In order to further study the molecular interaction 
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between TLR9 and CpG-DNA, immunoprecipitation experiments were performed.  
Fluorescently-labeled TLR9 as well as TLR4 were incubated with biotinylated CpG-
DNA.  CpG-DNA was able to precipitate TLR9, but not TLR4, indicating that the 
interaction between TLR9 and CpG-DNA was specific.  The binding of biotinylated 
CpG-DNA was out-competed by unlabeled CpG-DNA, further demonstrating 
specificity of binding (Latz, Visintin et al. 2004).  Interestingly, GpC-DNA was also 
able to precipitate TLR9, and not TLR4, indicating that TLR9 is able to bind ODNs in a 
sequence-independent manner.   
Many studies have also been undertaken to increase uptake of DNA into cells, 
and to observe whether this would have any effect on activation of TLR9.  Use of the 
liposomal transfection reagent N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethylammonium 
propan methylsulfate (DOTAP) results in a more efficient delivery of DNA into the cell, 
and this has been shown to be coupled with increased TLR9 activation (Dalpke, Frank et 
al. 2006).  Both the stimulatory and the non-stimulatory forms of DNA can cause this 
effect (Gibbard, Morley et al. 2006).  DOTAP-mediated endosomal translocation of 
otherwise non-stimulatory vertebrate DNA or of certain non-canonical CpG motifs 
triggers dendritic cell activation in terms of cytokine production, such as type I IFN and 
IL-6.  The stimulatory activity of PTO-ODNs is TLR9 dependent, whereas 
phosphodiester DNA, such as vertebrate DNA, in addition trigger TLR9-independent 
pathways.  It has been proposed that the inefficiency of the natural route for DNA 
internalization prevents low affinity TLR9 ligands in endosomes from reaching 
threshold concentrations required for TLR9 activation.   
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1.3.6.3 Current Limitations to the Design of TLR9 Agonists 
The design of therapeutic TLR9 agonists has been slowed by the lack of 
information available for receptor-ligand interaction, as well as the absence of a 
convenient screening assay.  This is largely due to the difficulties inherent in purifying 
sufficient quantities of the receptor for biochemical studies.  Rather than being evaluated 
on their capacity to interact with the receptor, TLR9 ligands are evaluated on the basis 
of their ability to elicit cellular responses in immune cells.  This approach is limited in 
that it does not allow discrimination of ligand-binding events from the entire signaling 
process.  To address these issues, we wanted to develop a system that would allow us to 
purify sufficient functional ligand-binding TLR9 for ligand-binding experiments.  We 
required a system that would produce significant amounts of glycosylated, active and 
reasonably pure protein.  In this thesis, a heat shock system was investigated as a 
potential mechanism to overcome the problems with purifying active receptor 
(Kowalski, Gilbert et al. 1993).  This inducible, non-destructive system allows high 
levels of expression of foreign genes and protein products.  
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2.0 HYPOTHESIS AND OBJECTIVES 
Using an established heat shock system for expression of the ligand binding domain 
of human TLR9, sufficient quantities of active receptor will be produced for 
biochemical assays to characterize the ligand binding domain and gain insight in to 
ligand binding characteristics. 
 
Objectives: 
1. To express the ligand binding domain of human TLR9 in an active ligand-
binding form. 
2. To express sufficient quantities of recombinant TLR9 protein for biochemical 
characterization. 
3. To use recombinant human TLR9 to analyze ligand binding characteristics.
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3.0 MATERIALS AND METHODS 
3.1 Reagents, Supplies and Equipment 
Biological and chemical reagents and supplies used in the experiments 
throughout this thesis along with their commercial suppliers are listed in Table 3.1.  
 
3.2 Plasmid Construction/Cloning 
With some species-specific variations, TLR9 is a protein of approximately 1030 
amino acids; the N-terminal 750 residues contain 25 LRR motifs, residues 750-810 an 
extracellular C-terminal motif, residues 810-825 represent the predicted transmembrane 
region and residues 825-1030 the intracellular TIR domain.  As the ligand-binding 
region of TLR9 has not been well-characterized, we selected a region encompassing the 
entire ectodomain, amino acids 1-815, to represent the ligand-binding domain (LBD).  
Although amino acids 810-815 are predicted to lie within the transmembrane domain, 
we did not anticipate problems with the recombinant protein, such as solubility. 
 DNA encoding the ectodomain was PCR amplified, with the addition of a six 
residue histidine-tag at the carboxy terminus (see Table 4.1, page 80), using a plasmid 
containing the human TLR9 open-reading frame as a template (kindly provided by Dr. 
Grayson Lipford, Coley Pharmaceuticals, Wellesley, MA).  The resulting PCR product 
was cloned downstream of a bovine hsp70A promoter and the expression cassette stably 
integrated into Madin-Darby bovine kidney epithelial (MDBK) cells by a lentiviral 
delivery system (Rouas, Uch et al. 2002). 
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Table 3.1. List of selected chemical supplies, enzymes, and proteins. 
Chemicals Supplier 
Acetic Acid EMD 
Acrylamide Sigma 
Agarose, electrophoresis grade Invitrogen 
Ammonium chloride J.T. Baker 
Ammonium persulfate (APS) J.T. Baker 
Antibiotic/antimycotic solution Gibco 
N,N-Bis(2-hydroxyethyl)-glycine Sigma 
Bromophenol Blue Sigma 
5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) 
Sigma 
Chloroform:isoamyl alcohol Amersham Biosciences 
Coomassie Blue G250 Biorad 
Dithiothreitol (DTT) Biorad 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
Gibco 
Ethidium bromide Pharmacia Biotech 
Ethylenediamine tetraacetic acid (EDTA) Fluka BioChemika 
Fetal Bovine Serum (FBS) Gibco 
Glycerol Amersham Bioscience 
Glycine ICN Biomedicals 
Magnesium Chloride Sigma 
2-mercaptoethanol Sigma 
Methanol EMD 
N,N’-Methylene-bis-acrylamide ICN Biomedicals 
p-nitro-blue-tetrazolium (NBT) Sigma 
Phenol (glass distilled) Sigma 
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Sodium acetate Sigma 
Sodium chloride Sigma 
Sodium dodecyl sulfate EMD 
Sodium hydroxide EMD 
Sodium phosphate monobasic EMD 
Sodium phosphate dibasic EMD 
N,N,N’,N’-Tetramethylethlene-diamine 
(TEMED) 
Pharmacia Biotech 
 
TRIzol Reagent Invitrogen 
Tween 20 Biorad 
  
Enzymes Suppliers 
PNGase F New England Biolabs 
Trypsin Boehringer Ingelheim 
  
Antibodies Supplier 
α-TLR9 mouse mAB EMD  
Goat-α-mouse IgG Kirkegarrd & Perry Laboratories 
  
Plasmid and ODNs Supplier 
pFLAG-CMV2 Sigma 
PD-ODNs Invitrogen 
 
Supplier Addresses 
Amersham Pharmacia Amersham Biosciences, Pittsburgh, PA, 
USA. 
Biorad Bio-Rad Laboratories Ltd., Mississauga, 
ON, Canada 
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Boehringer Mannheim Boehringer Ingelheim Ltd., Laval, QC, 
Canada. 
EMD Bioscience VWR Canlab, Mississauga, ON, Canada. 
Fluka BioChemika Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada. 
Gibco Invitrogen Ltd., Gaithersburg, MD, USA. 
ICN Biomedicals ICN Biomedical Canada Ltd., Saint 
Laurent, PQ, Canada. 
Invitrogen Invitrogen Canada, Inc., Burlington, ON, 
Canada. 
J.T. Baker Mallinckrodt Baker, Inc., Phillipsburg, NJ, 
USA.  
Kirkegarrd & Perry Laboratories, Inc. KPL, Inc., Gaithersburg, MD, USA. 
New England Biolabs NEB Ltd., Pickering, ON, Canada. 
Novagen VWR Canlab, Mississauga, ON, Canada. 
Pharmacia Biotech Pfizer Canada, Inc., Mississauga, ON, 
Canada. 
Sigma Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada. 
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 3.3 Heat Shock System 
3.3.1 Vector System and Cell Line Creation 
A eukaryotic expression system utilizing the bovine hsp70A gene promoter to 
direct the heat-regulated synthesis of proteins in transfected bovine kidney epithelial 
cells was used to express human TLR9(LBD), as described (Figure 3.1). 
Stably transfected MDBK cells were obtained from Dr. Robert Brownlie 
(VIDO), who, having used the lentiviral delivery system, performed cloning of our 
isolated TLR9(LBD).  Briefly, the cell line was made by transducing MDBK cells with 
a pseudolentivirus containing the construct.  To make the pseudovirus, human 
embryonic kidney (HEK) 293T cells were transfected with three plasmids: one 
containing the VSG envelope protein, one containing packaging functions and the other 
containing the TLR9(LBD) flanked by HIV long terminal repeat (LTR) regions.  The 
lentiviral vector also contained the gene encoding resistance to neomycin to aid in the 
selection process. 
 
3.3.2 Cell Line Maintenance 
MDBK cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotic/antimycotic solution (10,000 U penicillin, 10 mg streptomycin, 25 µg 
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Figure 3.1.  Expression of hTLR9(LBD).  The expression plasmid pLent-HS-
humanTLR9 containing the bovine hsp70A heat-shock gene promoter (BoHSP70A).  
The promoter was used to direct the heat-regulated synthesis of human TLR9 ligand 
binding domain [hTLR9(LBD)] in stably transfected bovine kidney (MDBK) cells.  A 
neomycin resistance cassette (Neo) was included in the plasmid for positive selection of 
transfected cells.  Restriction endonuclease cut sites are shown on the external ring. 
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amphotericin B per 25 mL) in Corning T75 culture flasks and incubated at 37oC/5% 
CO2. 
Confluent cell monolayers were treated with trypsin, a serine protease used to re-
suspend cells adherent to tissue culture dishes.  Media was removed from a flask 
containing a confluent monolayer of cells and cells were rinsed with 5 mL of Versene to 
remove residual FBS, which may inhibit the action of trypsin, and to increase the effect 
of trypsin by taking up calcium and magnesium ions.  Another 5 mL of Versene plus 
approximately 1 mL of 5% trypsin was added to the flask and the cap tightened.  After 
30 second incubation the Versene/trypsin solution was removed from the flask, the cap 
tightened slightly and the flask incubated at 37oC in a 5% CO2 atmosphere for 1-2 
minutes, or until cell detachment was observed.  Ten milliliters of fresh DMEM 
supplemented with FBS and antibiotic/antimycotic solution (as above) was added to the 
flask to resuspend the cells.   
On day 0, cells were grown to confluence in a single T75 culture flask.  The next 
day (day 1), cells were split in to two T150 culture flasks.  After incubating for two days 
to allow cells to become confluent (day 3), cells were split 1:2 in to four T150 flasks.  
Two days following (day 5), cells were split 1:4 in to sixteen T150 flasks.  Three days 
later (day 8), cells were split 1:2 in to 32 T150 flasks and the next day (day 9) cycle one 
of heat-shock began.  Ten cycles of heat shock followed (days 10 through 18). 
 
3.4 Overexpression of TLR9(LBD) 
Confluent cells in thirty-two T150 culture flasks were washed twice in serum-
free medium to remove serum from the cells, and incubated at 39oC/5%CO2 to induce 
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protein expression.  At the end of a 6 hour incubation period, flasks were returned to 
37oC/5%CO2 for 18 hours to allow expression of the protein.  At the end of a 24 hour 
cycle, the media was collected and centrifuged for 5 minutes at 2,000xg to remove cells 
and debris.  Culture medium was replaced with fresh serum-free DMEM and the cycle 
repeated 10 times.  Every 24 hour cycle yielded 640-800 mL of media (approximately 
0.1 mg of protein per liter as determined by Bradford protein quantification).   
An advantage of this expression system is that the recombinant protein is 
secreted into the culture medium, greatly facilitating collection and further purification.  
Although yields of the protein are relatively low, the non-destructive nature of this 
system permits large-scale production by splitting the culture and though ongoing heat 
shock cycling.  Relatively large quantities of the protein could be produced from ten 
rounds of temperature shifting with thirty-two T150 culture flasks.   
The secreted TLR9(LBD), containing a histidine-tag, was then purified using 
commercially available Nickel-columns (His-Bind Quick 300, Novagen).  Buffer 
compositions were as follows: 8x binding buffer, pH 7.9 [23.38% (w/v) NaCl, 16% 
(v/v) Tris-HCl, 0.27% (w/v) imidazole]; 8x wash buffer, pH 7.9 [23.38% (w/v) NaCl, 
16% (v/v) Tris-HCl, 3.27% (w/v) imidazole]; 4x elution buffer, pH 7.9 [11.69% (w/v) 
NaCl, 8% (v/v) Tris-HCl, 27.22% (w/v) imidazole].  Seven milliliters 1x binding buffer, 
2.5 mL 1x wash buffer and 1 mL 1x elution buffer were prepared (per cartridge) by 
diluting stocks to 1x with ddH2O.  One His-Bind cartridge was attached to a 10cc 
syringe and buffers pushed through at a rate of approximately 2 drops per second.  The 
cartridge was first wet and equilibrated with 2 mL 1x binding buffer.  Media containing 
secreted TLR9(LBD) was passed through the column 5 mL at a time (total volume: 20 
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mL) and then the cartridge washed with 5 mL 1x binding buffer.  The cartridge was 
washed with 2.5 mL 1x wash buffer prior to elution with 1 mL 1x elution buffer. 
Following this purification a single protein species was observed, which was 
bound by a monoclonal antibody directed against the extracellular domain of human 
TLR9, demonstrated by Western blotting.  However, our assays were not dependent on 
the absolute purity of the protein, and as such were carried out with protein which had 
not been purified with a Nickel-column. 
 
3.5 Western Blot Analysis 
3.5.1 SDS-PAGE 
Protein samples were denatured and resolved through a 10% SDS gel (10% bis-
acrylamide, 25% 1.5 M Tris pH 8.8 (v/v),  0.1% SDS, 48.4% (v/v) ddH2O, 0.05% APS, 
0.01% TEMED) with a 4% stacking gel [4% bis-acrylamide, 25% (v/v) 0.5 M Tris-HCl 
pH 6.8, 0.1% SDS, 63.4% (v/v) ddH2O, 0.05 % APS, 0.01% TEMED] in 1x SDS 
running buffer [0.3% (w/v) Tris base, 1.44% (w/v) glycine, 0.1% (w/v) SDS].  Samples 
were run at 90 V through the stacking gel and 180V through the resolving gel.   
The SDS gel was stained using a Coomassie G250 staining protocol.  The gel 
was incubated in fixation solution [50% (v/v) ethanol, 2% (v/v) orthophosphoric acid, 
48% (v/v) ddH2O] for 2.0 hours and subsequently incubated in G250 stain solution 
[34% (v/v) methanol, 17% (w/v) ammonium sulfate, 2% (v/v) orthophosphoric acid, 
0.1% (w/v) Coomassie G250, 64% (v/v) ddH2O] for a minimum of 4 hours, up to 16-18 
hours.  Following staining the gel was rinsed 1x with destaining solution [25% (v/v) 
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methanol] and destained for 1-2 hours, with an absorbing sponge placed in the destain 
for more complete destaining. 
A gel was run in parallel without staining for use in Western Blots. 
 
3.5.2 Western Blots 
After resolution through the SDS gel, proteins were electrophoretically 
transferred to a nitrocellulose membrane essentially as described (Towbin, Staehelin et 
al. 1979).  Nonspecific binding sites were blocked by incubating the nitrocellulose for 
1.0 hour in TBST buffer (0.1 M Tris-HCl, 170 mM NaCl, 0.05% Tween-20 pH 7.5) 
containing 3% skim milk.  Membranes were incubated for 1 hour in primary antibody 
(α-human TLR9 diluted to 2 µg/mL in TBST) and then for 1 hour with alkaline 
phosphatase-conjugated goat anti-mouse IgG (H+L) (0.5 µL/mL in TBST).  After being 
washed, membranes were developed with 5-bromo-4-chloro-3-indolyl phosphate nitro-
blue tetrazolium substrate (BCIP/NBT).  Anti-human TLR9 was obtained from 
Oncogene Research Products (EMD Biosciences) and goat anti-mouse IgG from 
Kirkegarrd and Perry Laboratories, Inc. 
 
3.5.3 Deglycosylation of TLR9(LBD) 
Purified TLR9(LBD) was treated with peptide N-glycosidase F (PNGase F) as 
follows.  Twenty µg of TLR9(LBD) was denatured in 5% SDS with 0.4 M dithiothreitol 
(DTT) for 10 minutes at 100oC.  Following this, reaction buffer (0.5 M sodium 
phosphate, pH 7.5) and 10% NP-40 were added at 1/10 reaction volume with 2.5 µL of 
PNGase F (0.278 mg/mL).  The deglycosylation was allowed to proceed at 37oC for 1 
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hour.  Samples were visualized by SDS-PAGE and Western blotting, as described 
previously (sections 3.5.1 and 3.5.2). 
 
3.6 Agarose Electrophoretic Mobility Shift Assays 
3.6.1 DNA Binding Assays 
Unless otherwise specified, DNA binding assays were performed with the 
incubation of 8 µg TLR9(LBD) (20 mM PBS pH 7.2, 100 mM NaCl, 0.5 mM β-
mercaptoethanol) with 1.4 µg DNA [pFLAG-CMV2 expression vector (Sigma) (Figure 
3.2)] in the presence of 10 mM MgCl2.  Reactions were buffered with 100mM sodium 
acetate (pH 5.2) to a final volume of 50 µL.  Reactions were incubated at 37oC for 10 
minutes and stopped with the addition of 10 µL 30% glycerol and immediately 
electrophoresed. 
 
3.6.2 Agarose Gels 
DNA binding assays were electrophoresed through a 0.8% agarose gel in TAE 
buffer [24.2% (w/v) Tris, 5.7% (v/v) glacial acetic acid, 50 mM EDTA] at 95 V for 1-2 
hours.  DNA was visualized by ethidium bromide staining: 1-3 µL of ethidium bromide 
was added to each 75 mL agarose gel prior to electrophoresis. 
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 Figure 3.2.  pFLAG-CMV2 used in binding assays.  Expression is driven by the CMV 
promoter, and restriction endonuclease cut sites are shown on the external ring.  The 
multiple cloning site (MCS) and ampicillin resistance cassette (Amp) are shown.  The 
plasmid contains six CpG motifs to serve as a ligand for human TLR9. 
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3.6.3 Supershift Assays 
Supershift assays were performed by the same methodology described for the 
mobility shift assays with the exceptions that the TLR9(LBD) was dialyzed against 50 
mM PBS pH 7.2, 100 mM NaCl and reactions were performed at pH 7.2 (50 mM Tris)  
to remove any small molecules which may influence the strength and specificity of the 
DNA:protein interaction.  The TLR9 monoclonal antibody used was the same as that 
used in Western blot analysis.  The reaction mixture was incubated for 1 hour at 37oC 
prior to electrophoresis. 
 
3.6.4 Freeze-Squeeze Method for Protein Extraction from Agarose 
Following agarose electrophoresis, bands corresponding to the nucleoprotein 
complexes were excised and placed in microcentrifuge tubes.  Tubes were frozen at -
80oC overnight.  Samples were thawed at room temperature and centrifuged at 14,000 
rpm for 10 minutes.  The supernatant was extracted for further analysis. 
 
3.6.5 Oligodeoxynucleotides 
The sequences of ODNs used in this investigation are presented in Table 3.2. 
PD-ODNs were purchased from Invitrogen. 
 
3.7 Establishment of Toll-like Receptor 9 Knockout Cell Line 
3.7.1 Generation of Knockout Mice 
TLR9-/- mice were generated by Hemmi  et al (Hemmi, Takeuchi et al. 2000) by 
disrupting the TLR9 gene with homologous recombination, and bred on a C57Bl/6  
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Table 3.2.  Oligodeoxynucleotides used in this investigation. 
ODN Name Sequence 
Human CpG GGATCAGCGGAGGTCGTTTTGTCGTTCTCTGTC 
Human GpC GGATCGACAGAGAACGACAAAACGACCTCCGCT
Mouse CpG GGATCAGCGGAGGACGTTCTGACGTTCTCTGTC 
Mouse GpC GGATCGACAGAGAACGTCAGAACGTCCTCCGCT 
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background.  Breeding pairs of TLR9-/- mice were supplied to VIDO by Dr. Heather 
Davis and mice were bred at VIDO. 
 
3.7.2 Generation of Cell Line 
The fibroblast cell line was generated from cells which grew out of tissue 
collected from the abdominal wall (muscle and subcutaneous tissue) of TLR9-/- mice.  
Cells were initially maintained in Minimum Essential Media (MEM) supplemented with 
10% FBS and 1% antibiotic/antimycotic solution (10,000 U penicillin, 10 mg 
streptomycin, 25 µg amphotericin B per 25 mL).  After one week, cells were maintained 
in MEM + 20% FBS + 1% antibiotic/antimycotic solution in order to enrich the culture, 
as cell proliferation, in most cases, increases with increasing concentrations of FBS.  
Cells were passaged until fibroblasts became the dominant cell type in culture, at 
approximately seven weeks. 
 
3.7.3 Confirmation of TLR9-/- Cells 
3.7.3.1 Protein Isolation  
TLR9-/- cells were seeded at 2.5 x 104 cells per well in 24-well plates and 
incubated at 37oC/5%CO2 for two days, until confluent.  Following 5 minute 
centrifugation at 2,500 rpm, to pellet the cells, and rinsing with 0.5 mL PBS, cells were 
lysed directly in culture plates by adding 500 µL TRIzol reagent (Invitrogen) to each 
well, and passing the cell lysate through a pipette.  Lysed samples were incubated for 5 
minutes on ice and then 5 minutes at room temperature (15oC to 30oC, according to 
manufacturers protocol) to permit complete dissociation of nucleoprotein complexes.  
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The lysates from two replicate wells were pooled into an Eppendorf tube and 200 µL of 
chloroform was added per 1.0 mL of TRIzol reagent (200 µL chloroform per tube).  
Tubes were shaken vigorously for approximately 15 seconds and incubated 2-3 minutes 
at room temperature.  Samples were then centrifuged at 12,000xg for 15 minutes at 2-
8oC.  Following centrifugation, the mixture separates into a lower red, phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase.  The colorless 
(RNA) phase and interphase (DNA) were removed, and 300 µL 100% ethanol added to 
the red phenol-chloroform portion of each tube in order to precipitate any remaining 
DNA.  Samples were inverted to mix, and incubated 2-3 minutes at room temperature.  
Following 5 minute centrifugation at 2,000xg the supernatant was collected for protein 
isolation.  Proteins were precipitated from the phenol-ethanol supernatant with 1.5 mL 
isopropyl alcohol added per tube.  Samples were stored for 10 minutes at room 
temperature, and the protein precipitate sedimented at 12,000xg for 10 minutes at 2-8oC.  
The supernatant was removed and the pellet in each tube washed 3x in a 1.5 mL of a 
solution containing 0.3 M guanidine hydrochloride in 95% ethanol.  During each wash 
cycle, samples were incubated for 20 minutes at room temperature then centrifuged at 
7,500xg for 5 minutes at 2-8oC.  After the final wash, protein pellets were vortexed in 
1.5 mL ethanol and incubated at room temperature for 20 minutes.  Following this 
incubation, samples were centrifuged at 7,500xg for 5 minutes at 2-8oC.  Pellets were air 
dried or vacuum dried then dissolved, by adding 100 µL 1% SDS per tube.  Complete 
dissolution of the protein pellet in some cases required incubating the sample at 50oC.  
Samples were centrifuged at 10,000xg for 10 minutes and the supernatants transferred to 
fresh Eppendorf tubes for storage at -5oC to -20oC.   
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Western blots were carried out as described previously.   
 
3.7.4 Transfections 
Fibroblast cells were transfected with a GFP-expressing plasmid using Fibroblast 
Transfection Reagent (Altogen Biosystems) in 24-well plates.  Two to five microliters 
of transfection reagent was incubated with 500 ng-1 µg pCANGFP DNA in 40 µL 
serum-free MEM for 15-30 minutes.  Cells were plated at 2.5x104 cells/well (in MEM + 
10% FBS) and transfection complexes were added (after incubation).  Plates were 
incubated at 37oC/5%CO2 for 24 hours, after which the media was replaced with fresh 
MEM + 10% FBS.  Transfection efficiency was assessed at 48h post-transfection and 
72h post-transfection by staining the nuclei with 4'-6-Diamidino-2-phenylindole (DAPI)  
and visualizing using a fluorescence microscope.
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4.0 RESULTS 
4.1 Expression and Purification of Toll-like Receptor 9 
In spite of the considerable therapeutic interest in TLR9 it has been difficult to 
design and screen TLR agonists due to the technical difficulties associated with 
purification of the receptor for biochemical characterization, including the production of 
the protein in its active form, with conservation of the normal post-translational 
modifications found on the endogenous receptor.  Accordingly, little information is 
available regarding the structural and ligand-binding properties of TLR9 and most of the 
assumptions regarding TLR9 ligand binding specificity have been extrapolated from cell 
stimulation experiments. 
Here, the ectodomain of human TLR9 [TLR9(LBD)] was expressed as a soluble 
protein by using a novel expression system for the purpose of investigation of its ligand-
binding properties.  The primary objective in the expression of the TLR9(LBD) was to 
obtain sufficient quantities of the active protein for biochemical characterization.  As the 
assay system that we employed to characterize nucleic acid binding by TLR9 is not 
dependent upon absolute purification of the receptor, this enabled us to focus on the 
generation of sufficient quantities of the active ligand-binding domain.  The caveat of 
these assays is that they require large amounts of protein.  We investigated the use of a 
proprietary eukaryotic heat shock system established at VIDO which has proven 
successful for the expression of other glycosylated proteins (Kowalski, Gilbert et al. 
1993). 
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4.1.1 Over-expression via Heat Shock
The expression of human TLR9 in mammalian cells using this heat shock system 
was the proposed solution to the problems associated with purification of TLRs, as it has 
certain advantages:  a) bacterial expression systems do not have the cellular machinery 
in place to glycosylate proteins; using a eukaryotic expression system, the protein is 
produced in a glycosylated form, b) the protein is secreted into media and is, therefore, 
easy to collect and c) the system is robust in that, although there is low protein yield 
with each cycle of heat shock, the cycle can be repeated upwards of fifty times and d) 
the secretion of the protein into the media provides an efficient means to separate the 
recombinant protein from cellular proteins. 
The heat-shock vector system is highly inducible.  Initial experiments at VIDO 
using this heat shock system to direct synthesis of proteins were carried out at 43oC, 
although lower induction temperatures had been shown to be more effective for certain 
proteins.  Our experiments were carried out with inductions at both 42oC as well as 
39oC.  Results from our initial experiments indicated that the induction of heat shock at 
39oC was preferable to induction at 42oC, as synthesis of larger amounts of protein was 
visible on the SDS gels (Figure 4.1).  Cells were maintained at 37oC, as is the optimal 
growth temperature for this cell type.  Of note, the protein visible in the SDS gels is 
bovine serum albumin (as confirmed by mass spectrometry, data not shown).  The 
amount of TLR9(LBD) protein produced is very small and is therefore difficult to 
visualize on an SDS gel.    
Madin-Darby bovine kidney (MDBK) cells were initially transduced with a 
pseudolentivirus containing our TLR9(LBD).  The final lentiviral vector contained the  
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 Figure 4.1.  A) SDS-PAGE of media collected from heat shock inductions at 42oC.  
Proteins were resolved through a 4% stacking gel followed by a 12% running gel.  Lane 
1 - broad range protein biomarker.  Lane 2 – 250 µg protein from supernatant.  Lane 3 – 
50 µg protein from supernatant.  Lane 4 – 10 µg protein from supernatant.  B) SDS-
PAGE of media collected from heat shock inductions at 39oC.  Proteins were 
resolved through a 4% stacking gel followed by a 12% running gel.  Lane 1 - broad 
range protein biomarker.  Lane 2 – 250 µg protein from supernatant.  Lane 3 – 50 µg 
protein from supernatant.  Lane 4 – 10 µg protein from supernatant.  Proteins were 
visualized via staining with Coommassie blue G250 stain as described (Section 3.5.1). 
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gene encoding resistance to neomycin to aid in the selection process.  Cells which 
survived treatment with neomycin were propagated and maintained as described.     
For our purposes, thirty-two T150 culture flasks, each containing 20-23 mL of 
media, were used for each cycle of heat-shock.  The cycle was repeated ten times 
(Figure 4.2), generating approximately 7L of media. 
 
4.2 Western Blot Analysis 
The presence of a soluble form of the receptor in the media was confirmed 
through Western blot analysis.  The primary antibody was a monoclonal antibody 
corresponding to amino acid residues 268-284 of human TLR9.  Through Western blot 
analyses we have shown that the antibody binds our recombinant human TLR9(LBD) 
(Figure 4.3), whereas media collected from untransfected control cells was unreactive 
towards the antibody.  It is therefore unlikely that the monoclonal antibody was reacting 
with contaminating cellular proteins.  We observed a single protein species of 
approximately 170 kDa, which is considerably larger than that calculated for the protein 
component of the recombinant receptor of approximately 91 kDa (Table 4.1).  
However, TLR9 is known to be highly glycosylated, and the single species observed has 
a mass consistent with previous reports for glycosylated TLR9 (Latz, Schoenemeyer et 
al. 2004).   
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 Figure 4.2.  Schedule and induction of hTLR9(LBD).  Day 0: cells are grown to 
confluence in a single T75 culture flask.  Day 1: cells are split in to two T150 culture 
flasks.  Day 3: cells are split 1:2 in to four T150 flasks.  Day 5: cells are split 1:4 in to 
sixteen T150 flasks.  Day 8: cells are split 1:2 in to 32 T150 flasks.  Days 9-18: cycles 1 
through 10 of heat shock. 
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 Figure 4.3.  Western blot analysis of hTLR9(LBD).  Medium was collected from heat 
shocked cells and proteins were resolved through a 10% SDS-polyacrylamide gel and 
analyzed via Western blot with a monoclonal antibody to human TLR9.  Lane 1 – broad 
range protein biomarker.  Lane 2 – 10 µg protein from supernatant.   
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Table 4.1.  Amino acid sequence of the hTLR9(LBD). Calculated molecular weight: 
90.55 kDa with predicted glycosylation sites in boldface type and underlined (Weber, 
Morse et al. 2004), and histidine tag (6xH) at the carboxy terminus. 
 
1     MGFCRSALHP LSLLVQAIML AMTLALGTLP AFLPCELQPH GLVNCNWLFL KSVPHFSMAA 
61   PRGNVTSLSL SSNRIHHLHD SDFAHLPSLR HLNLKWNCPP VGLSPMHFPC HMTIEPSTFL 
121 AVPTLEELNL SYNNIMTVPA LPKSLISLSL SHTNILMLDS ASLAGLHALR FLFMDGNCYY 
181 KNPCRQALEV APGALLGLGN LTHLSLKYNN LTVVPRNLPS SLEYLLLSYN RIVKLAPEDL 
241 ANLTALRVLD VGGNCRRCDH APNPCMECPR HFPQLHPDTF SHLSRLEGLV LKDSSLSWLN
301 ASWFRGLGNL RVLDLSENFL YKCITKTKAF QGLTQLRKLN LSFNYQKRVS FAHLSLAPSF 
361 GSLVALKELD MHGIFFRSLD ETTLRPLARL PMLQTLRLQM NFINQAQLGI FRAFPGLRYV 
421 DLSDNRISGA SELTATMGEA DGGEKVWLQP GDLAPAPVDT PSSEDFRPNC STLNFTLDLS 
481 RNNLVTVQPE MFAQLSHLQC LRLSHNCISQ AVNGSQFLPL TGLQVLDLSH NKLDLYHEHS 
541 FTELPRLEAL DLSYNSQPFG MQGVGHNFSF VAHLRTLRHL SLAHNNIHSQ VSQQLCSTSL 
601 RALDFSGNAL GHMWAEGDLY LHFFQGLSGL IWLDLSQNRL HTLLPQTLRN LPKSLQVLRL 
661 RDNYLAFFKW WSLHFLPKLE VLDLAGNQLK ALTNGSLPAG TRLRRLDVSC NSISFVAPGF 
721 FSKAKELREL NLSANALKTV DHSWFGPLAS ALQILDVSAN PLHCACGAAF MDFLLEVQAA 
781 VPGLPSRVKC GSPGQLQGLS IFAQDLRLCL DEALSHHHHHH 
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4.2.1 Glycosylation 
Glycosylation is important for the function of TLRs and that it plays a role in 
influencing receptor surface presentation, trafficking and pattern recognition (Weber, 
Morse et al. 2004).  All of the TLRs are predicted to be glycosylated and as would be  
expected, these glycosylation sites are said to be present within the extracellular 
domains of the receptors.  For example, it has been demonstrated that glycosylation is 
important for the function of TLR3, as modifying glycosyl groups has a negative effect 
on TLR3 activity (Jingchuan, Duffy et al. 2006).  The convex (outer) surface of the 
ectodomain of TLR3, however, is proposed to be completely devoid of glycosylation, 
and therefore is predicted to be the site of ligand-binding.   
Weber predicted thirteen potential glycosylation sites for TLR9 (Weber, Morse 
et al. 2004) (Table 4.1).  As with other TLRs, these sites are presumably important for 
the function of the receptor, which is why the production of a glycosylated protein was 
important here. 
Glycosylation of the recombinant protein was verified using PNGase F (N-
glycosidase F) to remove N-linked sugar residues.  This deglycosylation resulted in a 
molecular weight shift to between the 83 kDa and the 175 kDa band (Figure 4.4).  
Though it is difficult to extrapolate a molecular weight between 83 and 175 kDa, the 
apparent molecular weight of the deglycosylated receptor is in agreement with the 
calculated weight of the recombinant protein (91 kDa), taking in to account that the 
protein may not have been completely deglycosylated. 
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Figure 4.4.  Western blot analysis of glycosylated and deglycosylated hTLR9(LBD).  
Proteins were resolved through a 7% SDS-polyacrylamide gel.  Lane 1 – broad range 
protein biomarker.  Lane 2 – 10 µg protein from supernatant.  Lane 3 – 20 µg protein 
from supernatant, treated with an N-glycosidase (PNGase F).  There is an obvious 
difference in molecular weight between the deglycosylated and glycosylated samples. 
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4.3 Agarose Electrophoretic Mobility Shift Assays 
Previous investigations of the ligand binding properties of TLR9 have relied on 
SPR technology.  One drawback to this approach is that either the receptor or the ligand 
is required to be immobilized on to a solid surface, which does not allow the complex 
receptor-ligand or receptor-receptor interactions to take place as they would in vivo.  A 
system which did not require immobilization of either receptor or ligand was designed  
in order to maintain the dynamic relationship between receptor and ligand.  Within 
agarose gels, plasmids normally resolve to two predominant species: a faster-moving 
supercoiled form and a slower-moving relaxed form (Oppenheim 1981).    
Through the use of a modified agarose electrophoretic moblity shift assays, we 
have been able to show that TLR9(LBD) binds plasmid DNA.  This assay provides 
information regarding nucleoprotein complex formation based on altered patterns of 
DNA migration in the presence and absence of a DNA binding protein.  In contrast to 
the acrylamide shift assays, this system allows large nucleoprotein complexes to be 
resolved.  It also allows high-throughput analysis in a manner that is not dependent on 
immobilization of the receptor or the ligand.  This permits more characterization of 
receptor/ligand dynamics with respect to the formation of higher order structures (Ozer, 
Mitsouras et al. 1998).  Within this system, patterns of nucleoprotein migration are 
dependent upon the charge to mass ratio of the complexes, as well as the formation of 
higher order structures that influence the overall size of the molecule.  Therefore, there 
is not a linear relationship between the calculated molecular mass and the distance 
migrated in the gel.  The shifts are quantitative in nature, permitting discrimination and 
visualization of nucleoprotein complexes of differing compositions.  This is of particular 
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value for discrimination of nucleic acid binding by monomeric or dimeric forms of 
proteins as these complexes migrate as distinct entities. 
The TLR9(LBD) influences the migration of plasmid DNA, as shown by the 
formation of two distinct migrating species (Figure 4.5A).  It is of note that the faster 
moving unbound supercoiled plasmid is decreased in concentration.  It is likely that 
these two nucleoprotein species represent different stoichiometries of TLR9 binding to 
the plasmid.  These novel species are hypothesized to represent monomeric and dimeric 
forms of the receptor bound to a single plasmid.  These two species have since been 
verified as the monomeric and dimeric forms of the receptor binding the plasmid.  The 
concentrations of plasmid DNA in both the proposed monomeric and dimeric species 
were confirmed to be equivalent by quantification of band intensity using the AlphaEase 
imaging system.  Quantification is based on band intensity using ethidium bromide 
staining.  Ethidium bromide is an intercalating agent which fluoresces under  ultraviolet 
light, and binds uniformly to linear DNA molecules.  In our assay, we quantified the 
supercoiled form of the plasmid.  It has been demonstrated that ethidium bromide causes 
unwinding of DNA, without cutting (Radloff, Bauer et al. 1967), so we did not 
anticipate that there would be significant differences in band intensities due differences 
in the amount of ethidium bromide bound.  To determine the relative concentration of 
TLR9(LBD) present within each complex, the shifted bands were excised and proteins 
extracted by the freeze-and-squeeze method.  Western blot analysis with the monoclonal 
human TLR9 antibody confirmed that the intensity of the signal in the lane 
corresponding to the proposed dimeric form of the receptor is 1.95 times the inensity of 
the signal in the lane corresponding to the monomeric form of TLR9 (Figure 4.5B).   
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Figure 4.5.  A) Plasmid binding by hTLR9(LBD).  pCMV and TLR9(LBD) are used 
in constant quantities of 1.4 µg and 8 µg, respectively, in the presence of 10 mM MgCl2.  
Reactions were buffered with 100 mM sodium acetate (pH 5.2) and incubated at 37oC 
for 10 minutes and stopped with the addition of 30% glycerol.  Lane 1: pCMV; Lane 2: 
pCMV and TLR9(LBD), and Lane 3: pCMV and TLR9(LBD) boiled for 15 minutes 
prior to addition.  B) Confirmation of monomeric and dimeric nucleoprotein 
complexes.  The stoichiometry of the shifted nucleoprotein complexes was determined 
by comparing relative abundances of both nucleic acid and TLR9(LBD) within uniquely 
migrating species hypothesized to represent monomeric and dimeric forms of the TLR9 
nucleoprotein complex.  Relative band intensities were calculated for both the ethidium 
stained agarose gel to determine relative nucleic acid content as well as for Western 
blots of proteins extracted from these gel slices.  Results represent the averages of two 
trials. 
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This dimerization is not surprising as it has been shown that ligand-induced dimerization 
is a common theme within the Toll-like family (Choe, Kelker et al. 2005; Gay, Gangloff 
et al. 2006).   
Maintenance of a correctly folded structure is also important in plasmid binding.  
Deliberate disruption of the structure of the TLR9(LBD), by boiling for example, prior 
to its addition to the reaction mixture abolishes DNA binding activity (Figure 4.5, Lane 
3).  This demonstrates that the recombinant TLR9(LBD) is functional in terms of 
ligandbinding and can bind double-stranded DNA, a point of contention in the literature.  
The ligand used in this assay system is a closed circular plasmid which is present in both 
relaxed and supercoiled forms.  Importantly, the TLR9(LBD) was observed to associate 
preferentially with the supercoiled forms of plasmids.  This may account for the 
discrepancies reported with respect to the efficiency of plasmid binding by TLR9.  
Investigations reporting minimal association with plasmid have employed linear, 
double-stranded ODNs, while those supporting plasmid binding have used circular 
plasmids (Cornélie, Hoebke et al. 2004; Latz, Schoenemeyer et al. 2004; Rutz, Metzger 
et al. 2004).  The inability of the linear, double-stranded molecules to form supercoiled 
species would significantly reduce their efficiency as TLR9 ligands.  The ability to 
discriminate the binding of two configurations of the same plasmid is a unique and 
unexpected advantage of this screening system. 
 
4.3.1 Supershift Assays 
To ensure that the differential patterns of migration occurred as a result of the 
binding of TLR9(LBD), a supershift assay was performed utilizing a monoclonal 
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antibody to the ectodomain domain of human TLR9 (Kindrachuk, Potter et al. 2007).  
The incorporation of the monoclonal antibody into the nucleoprotein complex will result 
in a shifted pattern of migration compared to that of the nucleoprotein complex in the 
absence of antibody.  In the presence of the antibody, a differentially migrating band of 
the plasmid was observed, confirming the presence of TLR9(LBD) in the nucleoprotein 
complex (Figure 4.6).  The ability of the antibody to bind the recombinant protein was 
verified through conventional Western blot analysis (Figure 4.3).  The existence of 
monomeric and dimeric forms of the receptor was confirmed via quantification of band 
intensity and Western blotting as described (Figure 4.5B).   
 
4.3.1.1 ODNs Exert a Cooperative Effect on Plasmid Binding 
Using the agarose shift assays, we have also demonstrated that ODNs promote 
plasmid binding by TLR9.  In the absence of ODN, there is no formation of dimeric 
species observed.  This suggests a positive cooperative effect whereby the binding of 
substrate, in this case nucleic acids, to the binding site causes activation, rather than 
inhibition, of complex formation.  Unlike plasmid DNA, the limited net charge of an 
ODN is insufficient to cause migration of TLR9(LBD) into an agarose gel.  As such, 
direct visualization of ODN binding is not possible through the agarose gel shift system.  
It is possible, however, to monitor the association of ODNs with TLR9(LBD) through 
their impact on TLR9(LBD)-plasmid complexes.  Based on the expectation that 
plasmids and ODNs bind to a conserved site on TLR9, it was anticipated that these 
molecules would function as competitive inhibitors of each other such that binding of 
either molecule would prevent binding of the other.  Rather than competing with  
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 Figure 4.6. Supershift binding assays with anti-TLR9 monoclonal antibody.  
Lane 1: pCMV and TLR9(LBD), Lane 2: pCMV, TLR9(LBD) and anti-TLR9 
monoclonal antibody (1.5µg).  pCMV and TLR9(LBD) are at constant concentrations of 
1.4 µg and 8 µg, respectively.  Supershift assays were performed by the same 
methodology described for the agarose shift assays with the exceptions that the 
TLR9(LBD) was dialyzed against 50 mM PBS pH 7.2, 100 mM NaCl and reactions 
performed at pH 7.2.  The reaction mixture was incubated for 1 hour at 37oC prior to 
electrophoresis. 
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plasmid for TLR9(LBD) binding, ODNs were found to promote plasmid binding by 
TLR9(LBD) (Figure 4.7).  This effect is independent of sequence as both activating and 
non-activating ODNs are equally efficient in promoting these effects.  This is 
demonstrative of positive cooperativity as we see the increased formation of dimeric 
species by titrating in increasing concentrations of ODN while the amounts of plasmid 
and protein remain the same.  The cooperative effect observed with ODNs promoting 
plasmid binding, as demonstrated with agarose shift assays, also occurs with plasmids 
promoting the formation of complexes between TLR9(LBD) and ODNs (Kindrachuk, 
Potter et al. 2007).  This supports the conclusion of sensitizing the receptor for ligand 
binding.  Therefore, it can be concluded that nucleic acids, independent of structure or 
sequence, promote TLR9 dimer formation with either single- or double-stranded nucleic 
acids able to perform this function. 
 
4.3.1.2 Positive Cooperativity 
The mutual cooperativity exerted by nucleic acids, either ODNs or plasmids, on 
binding of nucleic acids by TLR9(LBD) prompted the consideration of the physiological  
significance of this phenomenon.  Previous investigations of TLR9 activation 
have utilized cell proliferation assays, providing a valuable platform to monitor the 
significance of this cooperative effect in vivo (Bauer, Heeg et al. 1999; Krieg, Yi et al. 
1999).  Through cell proliferation assays it was demonstrated that the cooperative effect 
of nucleic acids on TLR ligand-binding is preserved in vivo.  The magnitude of cellular 
responses upon co-stimulation with plasmid and either CpG- or GpC- ODNs was higher 
than the sum of the individual responses to ODN or plasmid alone  
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 Figure 4.7.  A) Cooperative influence of CpG ODNs on plasmid binding.  ODNs 
exert a sequence-independent cooperative effect on plasmid binding.  pCMV vector and 
TLR9(LBD) are used in constant quantities of 1.4 µg and 8 µg respectively.  Lane 1: 
pCMV; Lane 2: pCMV and TLR9(LBD); Lanes 3-8: identical to lane 2 with the addition 
of serial 2-fold dilutions of CpG PD-ODN starting at 10 µg.  B) Cooperative influence 
of GpC ODNs on plasmid binding.  ODNs exert a sequence-independent cooperative 
effect on plasmid binding.  pCMV and TLR9(LBD) are used in constant quantities of 
1.4 µg and 8 µg respectively.  Lane 1: pCMV; Lane 2: pCMV and TLR9(LBD); Lanes 
3-8: identical to lane 2 with the addition of serial 2-fold dilutions of GpC PD-ODN 
starting at 10 µg.  All assays were carried out in the presence of 10 mM MgCl2 and 
buffered with 100 mM sodium acetate.  Reactions were incubated at 37oC for 10 
minutes and stopped with the addition of 30% glycerol.     
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(Kindrachuk, Potter et al. 2007).  Co-stimulation with GpC-ODN and plasmid resulted 
in an approximately two-fold lower induction than that of CpG-ODN and plasmid.  That 
a more potent induction of immune responses was observed with CpG- rather than CpG-
ODNs reflects the cooperative effect of plasmid-mediated activation by CpG-ODNs. 
 
4.4 Establishment of a TLR9 Knockout Cell Line 
Establishment of a TLR9-/- cell line will allow us to express various forms of 
TLR9, either wild-type and mutant, in order to determine cellular responses to various 
ligands.  Fibroblast cells normally express very low levels of TLR9, which explains 
their unresponsiveness to TLR9 ligands (Hornung, Rothenfusser et al. 2002; Kyburz, 
Rethage et al. 2003).  Murine embryonic fibroblasts respond normally to TLR1, TLR2, 
TLR4 and TLR6 ligands, suggesting that the TLR signaling infrastructure, absent TLR9, 
is present in these cells (Satta, Dunoyer-Geindre et al. 2007). 
The TLR9-/- fibroblasts were isolated from tissue isolated from the abdominal 
wall tissue of TLR9-/- mice.  The initial cell population included myocytes (muscle 
cells) as well as fibroblasts.  Cells were maintained and passaged in 10% FBS for one 
week prior to being supplemented with 20% FBS-containing media.  Within four weeks 
of initial culture, cells developed fibroblast-like foci and approximately two weeks later, 
cells developed contact inhibition and were increasing in density.  Seven weeks after 
initial culture, fibroblasts were the dominant cell type. 
  Using these knockout cells should provide us with a TLR9-null background, 
which will allow us to measure the responses of TLR9 to ligand stimulation with the 
appropriate negative control.   
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The cells had no detectable TLR9 protein expression, as verified via traditional 
Western blot analysis against proteins purified from cell extracts using TRIzol methods.  
There was no reaction between the α-human TLR9 monoclonal antibody and the 
proteins purified from the TLR9-/- cells.  Sequence alignment data (not shown) indicates 
that the epitope to which the antibody binds is 100% homologous between human and 
murine TLR9. 
 TLR9-/- mice generated by Hemmi and his group were genotyped and verified to 
be TLR9-deficient (Hemmi, Takeuchi et al. 2000; Babiuk, Mookherjee et al. 2004).  The 
mutated TLR9 allele was PCR amplified using specific primers, and it was confirmed 
that mice did not express TLR9 (Babiuk, Mookherjee et al. 2004).   
 
4.4.1 Transfections 
Transfection efficiency was assessed using a fibroblast transfection reagent and a 
GFP-expressing plasmid, and was optimized by testing different parameters.  The 
recommended amount of transfection reagent is 3.5 µL and the recommended amount of 
DNA for transfection is 500 ng.  Using these parameters, some transfection was 
observed, though it was well under the stated 90% that could be achieved under 
recommended parameters (Table 4.2).  Therefore, the amount of reagent and the amount 
of DNA were varied in an attempt to optimize transfection.  Transfection efficiency 
increased from ~2% to approximately 30-40% as parameters were optimized (Figure 
4.8).  Below the recommended volume of transfection reagent, transfection efficiency 
was very low, with almost no transfection seen at all with increasing concentrations of 
DNA.  While 500 ng DNA was the recommended amount of DNA to be used, 600 ng  
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Table 4.2.  Parameters tested for transfection of TLR9-/- fibroblast cells. 
Results indicated that 600-800 ng of DNA transfected with 3.5-4.5 µL of transfection 
reagent was the most efficient (++).  Below 3.0 µL of transfection reagent, transfection 
was negligible (-/+).  n/a indicates that transfections were not carried out under those 
conditions. 
 
Volume of transfection reagent (µL) 
Concentration of DNA 
(ng) 
2.0 µL
 
2.5 µL 3.0 µL 3.5 µL 4.0 µL 4.5 µL 5.0 µL 
500 ng -/+ -/+ + + + + + 
600 ng -/+ + + ++ ++ ++ + 
800 ng n/a n/a + ++ ++ ++ + 
1000 ng n/a n/a n/a + + + + 
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 Figure 4.8. Transfection of TLR9-/- fibroblast cells.  A) DAPI stained nuclei.  Cells 
were rinsed 2X with PBS and incubated with 0.5mL 300nM DAPI/well for 10minutes at 
room temperature.  Cells were then rinsed 2X with PBS and visualized under 
fluorescence microscope.   B) GFP-expressing cells.  Cells were visualized using a FITC 
filter on the fluorescence microscope.  C) Merging DAPI and GFP images.
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and 800 ng showed more efficient transfection at 3.5-4.5 µL transfection reagent.  
Increasing the amount of transfection reagent above 4.5 µL did not improve 
transfection.  Though transfection efficiency has increased from ~2% to approximately 
30-40%, it is still rather low.  Currently, we do not have the protocols in place to select 
for transfected cells.  Should transfection efficiency fail to increase to a level suitable to 
our needs, selection procedures will be the next avenue to pursue.
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 5.0 DISCUSSION AND CONCLUSIONS 
TLR9 has attracted considerable attention for its role in the initiation of innate 
immune responses and for the ability of synthetic nucleic acids to modulate TLR9 
signaling.  TLR9 agonists are under active investigation for a variety of clinical 
applications.  Given the emerging promise of this class of molecules, coupled with their 
potential to induce damaging consequences such as autoimmune disorders, it is timely 
and appropriate to characterize the structural parameters that define the TLR9-ligand 
interaction in order to facilitate the design of more efficient and specific agonists. 
The immunostimulatory action of bacterial DNA can be effectively mimicked 
with synthetic, single-stranded ODNs.  As therapeutic TLR9 agonists these ODNs have 
considerable advantage over bacterial DNA as a result of their defined sequences and 
structures, their low costs of synthesis, and chemical stability, however they do require 
relatively high doses to induce innate immune responses and co-formulation is often 
necessary.   
CpG-ODNs are structurally complex molecules with numerous regions, 
including the nitrogenous bases, sugar groups and phosphodiester linkages which have 
the potential to influence their ability to serve as TLR9.  Modifications to the 2’ position 
of the sugar group (2’-O-methyl, 2’-O-methoxyethyl, for example) have been shown to 
decrease the effectiveness of ODNs, while modifications to the phosphodiester linkages 
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(addition of hydroxy, alkyl, or methyl groups) have also been shown to decrease the 
activity of ODNs (Vollmer, Weeratna et al. 2004; Kalota, Dondeti et al. 2006).  To 
elucidate the structure/immunological function relationship of TLR9 agonists, 
investigations have been conducted looking at how alterations of different regions of 
these molecules influence their ability to activate TLR9-dependent responses.   
The low cost, ease of production and stability of these DNA ligands make TLR9 
an attractive target amongst the TLRs for immunotherapeutic intervention.  The ability 
of CpG treatment to modulate immune responses has given rise to a number of 
therapeutic applications including: 1) priming the innate immune system to mediate host 
protection, 2) as adjuvants to promote induction of antigen-specific immune responses, 
3) as anti-allergens through establishment of TH1 responses, 4) in the treatment of a 
variety of malignancies and 5) for improved vaccination efficiency of individuals with 
poor immune responses (Zimmermann, Egeter et al. 1998; Krieg, Yi et al. 1999; Dittmer 
and Olbrich 2003; Klinman 2004; Lazarczyk, Grzela et al. 2005).  As immunoprotective 
agents, CpG ODNs trigger plasmacytoid dendritic cells to secrete type I IFNs, which are 
known to limit the growth of bacteria and viruses by activating macrophages.  This is 
the beginning of a complex cascade which includes activation of natural killer (NK) 
cells.  Innate immune responses elicited by CpG DNA improve host resistance to 
infection.   
Currently, however, there is no structural ligand-binding information available 
for TLR9.  Crystallographic studies have been performed for the ectodomain of human 
TLR3, which has high sequence homology to TLR9 and also binds unmethylated 
nucleic acids within the acidic endosomal compartments.  However, rather than 
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resolving the mechanisms of nucleic acid recognition, these studies have proposed two 
conflicting models of ligand binding; Choe and coworkers propose the convex side of a 
dimerized structure to be the ligand-binding region (Choe, Kelker et al. 2005), while 
Bell and coworkers propose that a binding groove for double-stranded RNA lies within 
the inner cavity of a TLR3 monomer (Bell, Botos et al. 2005).  To date, there is no 
definite model of ligand binding for TLR3, or for TLR9. 
Thus, little consensus has been reached with regard to: 1) the efficiency of TLR9 
in binding dsDNA, 2) the requirement of CpG motifs for mediating ligand 
binding events, 3) the ability of TLR9 to recognize higher order motifs (beyond the CpG 
motif) in a species-specific fashion, 4) the influence of the phosphorothioate 
modification on receptor-ligand binding and 5) whether ligand binding is influenced by 
higher order mechanisms.  Our goal was to use recombinant TLR9 protein to address 
these issues. 
 
5.1 Ligand Binding Properties of Recombinant Toll-like Receptor 9
Ligands which activate TLR9 have been identified, and there is a basic 
understanding of the TLR9 signaling cascade.  Upon binding of the ligand to TLR9, the 
adaptor molecule MyD88 is recruited, via the TIR domain, leading to subsequent 
phosphorylation of IRAKs and IKKs.  This ultimately leads to the production of 
inflammatory cytokines by NF-κB and IFNα/β (and IFN-inducible genes) by IRF7.  
Characterization of the ligand-binding properties of TLR9 has been limited by the 
difficulty of purifying the receptor in sufficient quantity for biochemical analyses, and 
the absence of convenient screening assays.  Although cell stimulation experiments 
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provide valuable information regarding the in vivo interactions between biomolecules 
based on cellular responses, a danger of this type of approach is that complex 
physiological signals and responses are reduced to a single measured output which may 
overlook potential points of regulation within the system, such as phosphorylation 
events, interactions with adaptor molecules and other secondary signaling molecules, as 
well as any response generated that is different than the output being measured, making 
it difficult to reach conclusions with respect to ligand binding.   
In order overcome these problems, we used novel methods for the purification of 
the soluble, ligand-binding domain of human TLR9 and a convenient, high-throughput 
assay that permits comparative analysis of nucleic acid binding.  An advantage of the 
MDBK cell expression system is that the recombinant protein is secreted into the media 
following expression, thus eliminating the requirement for a cell lysis step.  This 
decreases the potential for co-purification of contaminating proteins which may 
influence characterization of TLR9(LBD).  Gel shift assay systems have a distinct 
advantage over surface plasmon resonance (SPR), the technique utilized by other in 
vitro investigations of TLR9 ligand binding, in that they do not require immobilization 
of either the receptor or the ligand. 
Using the present system we demonstrated stable nucleoprotein complex 
formation between the recombinant TLR9(LBD) and plasmid DNA molecules.  While it 
has been demonstrated that innate immune responses can be initiated by plasmid DNA 
(Krieg, Yi et al. 1995) and time course experiments verify that plasmids remain intact 
within the endosomes for a sufficient duration to serve as TLR9 ligands (Bennett, Gabor 
et al. 1985), previous investigations have reached opposing conclusions with respect to 
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the ability of TLR9 to bind plasmids.  While a system established by Cornélie and his 
group demonstrated effective binding of plasmids (Cornélie, Hoebke et al. 2004), Rutz 
reported a weak interaction between TLR9 and double-stranded ligands (Rutz, Metzger 
et al. 2004).  Our observation that the receptor undergoes preferential association with 
supercoiled species may account for the differing conclusions, and suggests that TLR9 
does bind dsDNA.  It was confirmed that the receptor was indeed binding supercoiled 
DNA by extraction of DNA from the nucleoprotein complex.  Isolated DNA was run 
through an agarose gel and migrated as a supercoiled species (data not shown).  In the 
investigation by Rutz, double-stranded ODNs, rather than plasmids, were employed as 
ligands.  The inability of double-stranded ODNs to form supercoiled species may 
account for their reduced efficiency as ligands.  In addition, SPR analysis requires 
immobilization of the receptor or ligand.  This immobilization may influence the 
receptor:ligand interaction and potential receptor:receptor interactions by limiting the 
range of conformations that the bound molecule could adopt, meaning that receptor 
dimerization could not occur. 
 
5.1.1 Sequence and Structural Specificity 
From investigations of immune cell responses the CpG motif has emerged as the 
important feature for TLR9-mediated cellular activation.  Investigations by Cornélie and 
Rutz have demonstrated a preference for CpG- rather than GpC-ODNs but reached no 
conclusions regarding the ability of the receptor to bind double-stranded nucleic acids 
(Cornélie, Hoebke et al. 2004; Rutz, Metzger et al. 2004).  It is generally assumed that 
this specificity for the motif is determined at the level of ligand binding by TLR9.  
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While CpG-specific activation of the innate immune responses has been assumed to 
reflect sequence-specific binding by TLR9, recent binding assays have reached 
contradictory conclusions with respect to the ability of the receptor to associate with 
nucleic acids in a sequence-specific manner (Cornélie, Hoebke et al. 2004; Latz, 
Schoenemeyer et al. 2004; Rutz, Metzger et al. 2004; Shirota, Gursel et al. 2004).  Our 
investigations may offer an explanation for this apparent discrepancy by demonstrating 
the ability of TLR9 to form both stable and highly sequence-specific nucleoprotein 
complexes, but also to be sensitized by nucleic acids in a sequence-independent fashion. 
Using in vitro binding assays, the ability for TLR9(LBD) to discriminate the 
CpG motif, as well as higher order sequences of six base pairs in length has been 
demonstrated.  The six base pair CpG motif preferentially bound by the recombinant 
human TLR9(LBD) in the presence of plasmid corresponded with the sequence that 
elicits the greatest in vivo responses in humans, GTCGTT.  In contrast, the murine 
motif, GACGTT, did not form nucleoprotein complexes with the recombinant receptor 
in the presence of plasmid (Kindrachuk, Potter et al. 2007).  As such, formation of stable 
complexes is highly sequence-dependent and this may dictate the specificity of 
activation of the innate immune system. 
 
5.1.2 Interaction versus Activation 
The sequence-specificity of the formation of stable nucleoprotein complexes 
suggests that the interaction between TLR9 and nucleic acids is sequence-dependent.  
However, that TLR9 has the ability to be functionally influenced by inhibitory nucleic 
acid sequences implies that the receptor has the ability to bind both stimulating and non-
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stimulating sequences, possibly highlighting the functional distinction between ligand 
binding and receptor signaling.  This is of particular consequence as it limits the 
potential to discover novel agonists when using a screening assay which only measures 
the ability an of agonist to interact with its receptor.   
In contrast to the sequence specificity of nucleoprotein complex formation our 
results also demonstrated the ability for both single and double-stranded nucleic acids to 
exert a cooperative effect on TLR9 ligand-binding in a sequence-independent fashion.  
In the presence of ODN, TLR9 is more efficient in binding plasmid and vice versa.  This 
effect is hypothesized to result from the requirement of TLR9 to form dimers in order to 
sample potential nucleic acid ligands for the presence activating motifs.  While non-
activating nucleic acids are rapidly released, the dimer formed persists momentarily and, 
during this time, is activated to bind other prospective ligands.  Others have noted that 
TLR9 displays low affinity binding to ODNs which is enhanced by the presence of CpG 
motifs, or increased ODN concentration, to a higher avidity form of the receptor 
(Yasuda, Rutz et al. 2006).  This observation is consistent with the model of 
cooperativity that we propose. 
 
5.1.3 Model of Cooperativity 
Using the model of cooperativity, a number of key issues with respect to the 
sequence and structural parameters that influence the ability of nucleic acids to function 
as TLR9 ligands can be resolved.  Sequences which are unable to mediate direct 
activation of TLR9 appear to influence the threshold of TLR9 activation by exerting a 
 104
positive cooperative effect on ligand binding in vivo and in vitro.  This is in contrast to 
the model of negative cooperativity shown with Drosophila Toll.    
It is hypothesized that the nucleoprotein complexes formed during the agarose 
shift assays correspond to monomeric and dimeric forms of the receptor (Figure 4.5).  
Dimerization is a common theme in the Toll and TLR family of receptors (Gangloff and 
Gay 2004; Weber, Moncrieffe et al. 2005).  These results may highlight the difference 
between activation and interaction.  Cell stimulation experiments demonstrate that CpG- 
rather than GpC-containing ODNs preferentially activate the innate immune system, 
which would suggest that nucleic acids bind TLR9 in a sequence-dependent manner.  
Conversely, immunoprecipitation experiments have shown that both CpG- and GpC-
containing ODNs interact with TLR9, suggesting that nucleic acid binding to TLR9 is 
sequence-independent (Krieg, Yi et al. 1999; Latz, Schoenemeyer et al. 2004; Rutz, 
Metzger et al. 2004).  Our observations that ODNs and plasmids, independent of their 
sequence, functionally influence TLR9 ligand binding are consistent with the conclusion 
that TLR9 has the ability to interact with, and be modulated by, nucleic acids in a 
sequence-independent fashion. 
Activation of Toll is proposed to begin with the existence of an inactive ligand-
free dimer and proceed through a two-step mechanism in which the formation of the 
active dimer is preceded by the formation of a monomeric ligand complex.  Spätzle, the 
ligand of Toll, also functions as a homotropic allosteric inhibitor to exert negative 
allosteric effects on formation of the active dimer.  Spätzle, upon binding to the active 
site of the first monomeric subunit of Toll, induces structural alterations which are 
translated to the second subunit via non-covalent associations.  These alterations reduce 
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the affinity of the second subunit for Spätzle, causing the second step to Toll activation 
to occur with an approximately three-fold lower affinity than the binding of the Spätzle 
by the first subunit (Gangloff, Weber et al. 2003; Gay, Gangloff et al. 2006).  This effect 
was reported as negative cooperativity and is proposed to increase the range of substrate 
concentrations to which Toll is responsive.  This mechanism has been verified in vitro at 
the level of ligand binding, as well as through kinetic characterization.  The authors 
hypothesized a similar mechanism may influence the activation of the Toll-like 
receptors (Gay, Gangloff et al. 2006).   
In contrast to the negative cooperativity reported for Toll, we have observed the 
ability for both single and double-stranded nucleic acids to exert a positive cooperative 
effect on TLR9 ligand binding; in the presence of ODNs, TLR9 is better able to form 
nucleoprotein complexes with plasmid molecules and conversely TLR9 is also better 
able to bind ODNs in the presence of plasmid.  This mutual allostery occurs in a 
sequence-independent fashion as CpG- and GpC-ODNs are equally effective in 
promoting plasmid binding by TLR9.  As described, this is hypothesized to result from 
the requirement of TLR9 to form dimers to sample potential nucleic acid ligands in 
order to discriminate activating from non-activating nucleic acids.  While non-activating 
nucleic acids are rapidly released by TLR9, the dimer persists and is activated with a 
higher affinity for binding of other nucleic acid ligands (Figure 5.1). 
The schematic presented illustrates the proposed equilibrium between the TLR9 
monomer, occupied dimer and ligand-free dimer.  This model requires TLR9 to 
associate with nucleic acids in a sequence-dependent fashion, at least momentarily.  The 
associations with non-activating ODNs are sufficient to cause dimer formation and shift  
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Figure 5.1.  Models of activation of Toll and Toll-like Receptor 9.  Activation of Toll 
is mediated through a two-step reaction.  The first binding event, to the formation of a 
ligand-bound monomer, occurs with high affinity.  The second stage of Toll activation, 
binding of the Toll-ligand monomer by a ligand-free monomer, occurs with lower 
affinity, representing negative cooperativity of activation.  Activation of TLR9 is 
proposed to follow a similar two-step reaction with the distinction being that the second 
step to dimer formation occurs with positive cooperativity. 
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the monomer-dimer equilibrium of TLR9 to the active form of the receptor.  Notable for 
TLR9 we did not observe the presence of labeled ODNs in plasmid:TLR9 nucleoprotein 
complexes which indicates that the ability to promote this complex formation does not 
involve the simultaneous binding of each type of nucleic acid.  For both Toll and TLR9, 
the allosteric modulators are also ligands in the sense that they are bound at the active 
site and as such represent homotropic modulators. 
Following the release of non-activating sequences, the ligand-free TLR9 dimer 
persists briefly.  Though this dimer is inactive, it has been sensitized and has an increase  
affinity for nucleic acids.  The binding of activating sequences by the ligand-free dimer 
would be hypothesized to induce structural alterations within the TIR domains of the 
TLR9 dimer leading to receptor activation.  In contrast to the Toll model, the 
conformational changes induced within TLR9 following the sequence-independent 
interaction with nucleic acids increase the affinity of the receptor for the stable binding 
of activating or non-activating sequences.  This results in the second step of TLR9 
activation proceeding with a much higher affinity than the first step.  The equilibrium 
between TLR9 monomers, ligand-bound dimers, and ligand-free TLR9 dimers is 
illustrated in Figure 5.1.  Supportive of this model of higher order functional influence 
of nucleic acids on TLR9 activation, the sequence-independent association of DNA with 
TLR9 has become been independently confirmed (Latz, Schoenemeyer et al. 2004; 
Yasuda, Rutz et al. 2006). 
Collectively these results demonstrate that nucleic acids influence TLR9 
functioning in both sequence-dependent and sequence-independent fashions.  While 
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the binding of ligands for activation of receptor signaling is highly sequence-specific, 
non-activating nucleic acids are able to modulate TLR9 ligand binding by altering 
ligand binding affinity.  That ODNs are able to modulate TLR9 function through 
influencing sensitivity helps to establish the ability of these molecules to interact with, 
but not directly activate, TLR9.  Taken together with the observations of Toll, this 
suggests that both of these receptor families activate through a two-step process with the 
initial binding event determining specificity while the second binding event dictates 
sensitivity in a positive or negative fashion. 
The physiological significance of this cooperative effect may be in determining 
the set point for activation of TLR9.  That increased quantities of nucleic acid are able to 
sensitize the system in a sequence-independent fashion suggests that release of nucleic 
acids following bacterial uptake within the phagosome primes the system for innate 
immune responsiveness if activating CpG motifs are present.  This dual requirement for 
activation may function as a safe guard to prevent the induction of inappropriate innate 
immune responses and for discrimination of self from non-self. 
The proposed model of cooperative sensitization of TLR9 is supported by cell 
stimulation experiments where the magnitude of proliferation responses to plasmid 
stimulation in the presence of either stimulatory or non-stimulatory natural ODNs was 
greater than the sums of activation that were elicited by either of these classes of 
molecules in isolation (Kindrachuk, Potter et al. 2007).  A recent report by Latz et al 
also supports these findings.  Using biochemical and fluorescence resonance energy 
transfer, fluorescence lifetime imaging microscopy and circular dichroism spectroscopy, 
they found that their recombinant TLR9 bound stimulatory and inhibitory DNA but only 
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stimulatory DNA led to conformational changes in the ectodomain of the receptor (Latz, 
Verma et al. 2007).  Activation of TLR9 is said to be regulated by conformational 
changes in the ectodomain induced by CpG-containing DNA.  This is consistent with 
our findings that TLR9 binds DNA in a sequence-independent manner but is activated in 
a sequence-dependent manner.   
 
5.2 CpG ODNs 
The observation that TLR9 can be functionally influenced by non-CpG elements 
expands the range of nucleic acids that can be employed to modulate innate immune 
responses through TLR9.  The design of novel TLR9 immunotherapeutics may benefit 
from consideration of TLR9 modulators, rather than direct activators.  These molecules 
would be selected on the basis of the ability to prime the TLR9 system for CpG-specific 
activation with the potential for co-formulation of activating and modulating molecules.   
 
5.3 Future Applications 
Attention has been brought to the therapeutic potential of TLR9 activation 
through various mechanisms including, but not limited to, innate immune activation 
with TH1-like cellular and cytokine/chemokine responses, as well as enhancing antigen-
specific humoral and cellular adaptive immune responses.  In spite of the considerable 
therapeutic potential of CpG-ODNs to activate TLR9, reasonable concerns have been 
raised with regards to their safety, particularly local inflammation, autoimmunity and 
excessive immune stimulation.   
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Current data would suggest that the receptor binds several motifs besides the 
natural CpG motif, and that these alternative recognition patterns produce different 
cytokine-secretion profiles.  Investigations of molecular recognition of modified CpG 
DNAs by different cells from a wide range of species would further define the process, 
and lead to the design of less toxic immunomodulators for therapeutic applications. 
Using our system of soluble TLR9(LBD) expression, we have developed a 
model which resolves a number of key issues with respect to the sequence and structural 
parameters that influence the ability of nucleic acids to function as TLR9 ligands, and 
permits comparative analysis of nucleic acid binding by the receptor.  The use of the 
heat shock system of expression of the recombinant receptor and the development of a 
convenient assay to screen for potential TLR9 ligands could advance the process of 
developing TLR9 agonists.  We have in place a system to determine not only the ability 
of ligands to bind the receptor, but also the ability of ligands to form stable complexes 
with the receptor for activation.  We have determined that the recombinant TLR9(LBD) 
binds ligands in a sequence-independent manner and, in contrast, presume that receptor 
activation is highly dependent on sequence.  Ligand binding by non-activating nucleic 
acids appears to be an important step in sensitization of the receptor to activating nucleic 
acids, as it has been demonstrated that, in the presence of plasmid, CpG-containing 
ODNs cause an increase in cell proliferation compared to GpC-containing ODNs 
(Kindrachuk, Potter et al. 2007).  These results are consistent with a TLR9-type 
response, though TLR9 is not the only TLR expressed in PBMCs (Armstrong, Medford 
et al. 2004; Werling, Hope et al. 2004).  Using the TLR9-/- fibroblast cell line, we could 
investigate the effect of activating and non-activating nucleic acids on a TLR9-null 
 111
background as a control.  To determine the role played by TLR9, the cells could be 
transfected with a TLR9 construct and assessed as such using activating and non-
activating nucleic acids. 
Though there is increasing evidence for cross-talk among various cell signaling 
pathways, such as B cell receptors and cytokine receptors (Hill 1998; Guo, Blair et al. 
2007), to date there is no evidence to suggest that TLR9 interacts directly with other 
receptors.  Our system would allow determination of not only receptor-receptor 
interaction, but also stable complex formation between receptors.  Pattern recognition 
receptors, including TLRs, are usually shared by cells of the innate immune system, 
including polymorphonuclear phagocytes, monocytes/macrophages, DCs and natural 
killer cells, though TLR9 is said to be confined to B cells and plasmacytoid dendritic 
cells in resting human immune cells (Krieg 2006).  All of these are cells with specialized 
function which cooperate to mount effective immune responses.  In theory, receptors 
could cross-talk with one another to increase and diversify recognition of microbial 
infection, as is the case with other members of the TLR family, including TLRs 1, 2 and 
6.   
Use of this system of expression is not limited to the TLR9(LBD).  The 
expression system can be modified to express any, or all, of the TLRs in order to 
elucidate their ligand binding properties as we have done with TLR9.  The ligand 
binding properties of the other nucleic acid binding TLRs (3, 7 and 8) could be 
investigated by a similar means as the TLR9(LBD), while other protein-binding 
receptors could be expressed using this system and investigated by other means.  
Investigation into the ligand binding properties of other TLRs is of particular importance 
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due to their roles in the induction of the innate immune system in response to a wide 
variety of pathogens.  Though there is an incredible amount of redundancy built in to the 
TLR signaling cascades, there is also a tremendous amount of specificity.  As such, it 
would be valuable to look beyond TLR9 as a potential for therapeutic intervention.
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